

Trying 3106016892...Open

9/124280

Welcome to STN International! Enter x:x  
LOGINID:ssspta1813nxm  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload  
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL  
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's  
DWPI and DPCI

NEWS EXPRESS July 11 CURRENT WINDOWS VERSION IS V6.0b,  
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:03:48 ON 09 AUG 2001

=> file embase medline biosis uspatfull japio wpids caplus agricola lifesci  
biotechds jicst-eplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'EMBASE' ENTERED AT 12:04:22 ON 09 AUG 2001  
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 12:04:22 ON 09 AUG 2001

FILE 'BIOSIS' ENTERED AT 12:04:22 ON 09 AUG 2001

COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 12:04:22 ON 09 AUG 2001  
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 12:04:22 ON 09 AUG 2001  
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'WPIDS' ENTERED AT 12:04:22 ON 09 AUG 2001  
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'CAPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 12:04:22 ON 09 AUG 2001

FILE 'LIFESCI' ENTERED AT 12:04:22 ON 09 AUG 2001  
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 12:04:22 ON 09 AUG 2001  
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JICST-EPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001  
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

=> e porro massimo/au

E1	11	PORRMANN VOLKER/AU
E2	1	PORRO/AU
E3	0 -->	PORRO MASSIMO/AU
E4	96	PORRO A/AU
E5	3	PORRO A D/AU
E6	11	PORRO A M/AU
E7	1	PORRO A R/AU
E8	1	PORRO A ROBERT/AU
E9	2	PORRO ABDO Y/AU
E10	1	PORRO ADALBERTO/AU
E11	12	PORRO ADOLFO/AU
E12	1	PORRO ADOLPHO/AU

=> e porro massimo/au

E1	1	PORRO MARIANO/AU
E2	1	PORRO MARIO/AU
E3	40 -->	PORRO MASSIMO/AU
E4	2	PORRO MIGUEL E/AU
E5	9	PORRO MONICA/AU
E6	1	PORRO N/AU
E7	1	PORRO NICHOLAS D/AU
E8	1	PORRO NOEL M/AU
E9	7	PORRO NOVO N/AU
E10	7	PORRO P/AU
E11	1	PORRO PAOLO/AU
E12	13	PORRO R/AU

=> s e3

L1 40 "PORRO MASSIMO"/AU

=> s l1 and bacteria

L2 20 L1 AND BACTERIA

=> dup rem 12

PROCESSING COMPLETED FOR L2  
L3 17 DUP REM L2 (3 DUPLICATES REMOVED)

=> d bib ab 1-17

L3 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:84285 CAPLUS  
DN 132:136410  
TI Vaccines for prevention of gram-negative bacterial infections and  
endotoxin-related diseases  
IN **Porro, Massimo**  
PA Biosynth S.R.L., Italy  
SO Eur. Pat. Appl., 40 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 976402	A2	20000202	EP 1999-202476	19990727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-124280		19980729		

AB A vaccine is disclosed which is useful for protecting a host from Gram  
neg. infections and the effects of endotoxin, therefore preventing sepsis  
and septic shock. The vaccine is prepd. by combining LPS free or in  
conjugate form with a stoichiometric excess of a peptide of the formula:  
(a) (A)<sub>n</sub> wherein A is Lysine or Arginine and n is an integer with a min.  
value of 7; (b) (AB)<sub>m</sub> wherein A is Lysine or Arginine and B is a  
hydrophobic amino acid selected from the group consisting of Valine,  
Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an  
integer with a min. value of 3; and (c) (ABC)<sub>p</sub> wherein A is a cationic  
amino acid which is Lysine or Arginine; B and C are hydrophobic amino  
acids which may be the same or different and are selected from the group  
consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and  
Tryptophan; p is an integer with a min. value of 2.

L3 ANSWER 2 OF 17 USPATFULL  
AN 1998:138863 USPATFULL  
TI Potentiation of antibiotics  
IN **Porro, Massimo**, Siena, Italy  
Varra, Martti, Haartmaninkatu, Finland  
PA Biosynth S.r.l., Italy (non-U.S. corporation)  
PI US 5834430 19981110  
AI US 1995-456112 19950531 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle,  
Jennifer  
LREP Hedman, Gibson & Costigan, P.C.  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with methods of potentiating an  
antibiotic. The invention also includes compositions of an antibiotic  
and a peptide having units of the formula:

(a) (A)<sub>sub.n</sub> wherein A is Lysine or Arginine and n is an integer with

a

minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions have potentiated antibiotic activity.

L3 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2001 ACS

AN 1998:344326 CAPLUS

DN 129:27010

TI Combined use of anti-endotoxin synthetic peptides and of anti-endotoxin antibodies for the prophylaxis and treatment of endotoxemia and septic shock

IN Porro, Massimo

PA Biosynth S.r.l., Italy

SO Eur. Pat. Appl., 5 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 842666	A2	19980520	EP 1997-203526	19971112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	IT 1996-MI2354		19961113		
AB	Methods and compns. for neutralizing endotoxin and for the prophylaxis and treatment of endotoxemia and septic shock are disclosed, which comprise the use of peptides specifically binding to the conserved endotoxin structure (Lipid A), and antibodies specifically binding to the antigenic determinants in the endotoxin core structure of different genera of Gram-neg. bacteria.				

L3 ANSWER 4 OF 17 USPATFULL

AN 97:66100 USPATFULL

TI Peptides for neutralizing the toxicity of Lipid A

IN Porro, Massimo, Siena, Italy

PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5652211 19970729

AI US 1993-97830 19930726 (8)

RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned, said Ser. No. US -49871 which is a continuation of Ser. No. US -658744

DT Utility

FS Granted

EXNAM Primary Examiner: Russell, Jeffrey E.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 39

ECL Exemplary Claim: 36,38

DRWN No Drawings

LN.CNT 683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with a peptide composition which includes a peptide having units of the formula:

a (a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L3 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2001 ACS

AN 1997:117658 CAPLUS

DN 126:141909

TI Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric **bacteria**. [Erratum to document cited in CA125:163069]

AU Vaara, Martti; **Porro, Massimo**

CS Dep. Bacteriology Immunology, Univ. Helsinki, Helsinki, 00014, Finland

SO Antimicrob. Agents Chemother. (1997), 41(2), 496

CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

AB The synthetic peptide KFFKFFKFF should read KFFKFFKFFK, and IKFLKFLKFL should read OKFLKFLKFLK. The index entries were cor.

L3 ANSWER 6 OF 17 USPATFULL

AN 96:120869 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN **Porro, Massimo**, Siena, Italy

PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)

PI US 5589459 19961231

AI US 1994-280397 19940726 (8)

RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,

Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Davenport, Avis M.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently

H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino

acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L3 ANSWER 7 OF 17 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 1  
AN 1996:433941 BIOSIS  
DN PREV199699147547  
TI Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric **bacteria**.  
AU Vaara, Martti (1); **Porro, Massimo**  
CS (1) Dep. Bacteriol. and Immunol., P.O. Box 21, Univ. Helsinki, 00014 Helsinki Finland  
SO Antimicrobial Agents and Chemotherapy, (1996) Vol. 40, No. 8, pp. 1801-1805.  
ISSN: 0066-4804.  
DT Article  
LA English  
AB A synthetic peptide, KFFKFFKFF, consisting of cationic lysine residues and hydrophobic phenylalanine residues was found to sensitize gram-negative **bacteria** to hydrophobic and amphipathic antibiotics. At a concentration of 3  $\mu$ -g/ml, it decreased the MIC of rifampin for smooth, encapsulated *Escherichia coli* by a factor of 300. Other susceptible bacterial species included *Enterobacter cloacae*, *Klebsiella pneumoniae*, and *Salmonella typhimurium*, but *Pseudomonas aeruginosa* was resistant. Similar results were obtained with another synthetic peptide, IKFLKFLKFL. The fractional inhibitory concentration indices for the synergism of these peptides with rifampin, erythromycin, fusidic acid, and novobiocin were very close to those determined for the previously characterized potent outer-membrane-disorganizing agents polymyxin B nonapeptide and deacylpolymyxin B. KFFKFFKFF had direct activity against the gram-positive organism *Micrococcus* strain ML36, was strongly hemolytic, and was as active on polymyxin-resistant *E. coli* mutants as on their parent. These three attributes made KFFKFFKFF different from polymyxin derivatives and similar to cationic detergents, such as cetylpyridinium chloride. However, whereas the MIC of cetylpyridinium chloride for *E. coli* is low (0.5 to 4  $\mu$ -g/ml), that of KFFKFFKFF is much higher (30 to 100  $\mu$ -g/ml). Other groups of synthetic peptides studied included polymyxin-like peptides with an intrachain disulfide bridge. Their synergism with antibiotics was less marked. Still other peptides, including K-EKEKEKEKE and KKKKKKFLFL, lacked any synergism with the probe antibiotics.

L3 ANSWER 8 OF 17 USPATFULL  
AN 94:106884 USPATFULL  
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock  
IN **Porro, Massimo**, Siena, Italy  
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5371186 19941206  
AI US 1992-819893 19920116 (7)  
DCD 20111025  
RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.  
LREP Hedman, Gibson & Costigan  
CLMN Number of Claims: 11

ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel peptides of the formula  $R_{sub.1}$ - $(A-B-C)_{sub.n}$ -R, where  $R_{sub.1}$  and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the

prevention

and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L3 ANSWER 9 OF 17 USPATFULL

AN 94:93312 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5358933 19941025

AI US 1993-49871 19930419 (8)

RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel peptides are disclosed which are based on the formula:

$R_{sub.1}$  (Lys-Phe-Leu) $_{sub.n}$ --R

wherein n is an integer of from 1-10 and R and  $R_{sub.1}$  are H or an amino

acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L3 ANSWER 10 OF 17 USPATFULL

AN 94:35369 USPATFULL

TI Oligosaccharide conjugate vaccines

IN Porro, Massimo, Siena, Italy

PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)

PI US 5306492 19940426

AI US 1992-921678 19920730 (7)

RLI Division of Ser. No. US 1990-590649, filed on 28 Sep 1990, now patented,

Pat. No. US 5153312

DT Utility

FS Granted

EXNAM Primary Examiner: Kim, Kay K.

LREP Dow, Kenneth J.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 1422

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the

invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide.

A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of *Streptococcus pneumoniae*.

L3 ANSWER 11 OF 17 BIOSIS COPYRIGHT 2001 BIOSIS  
AN 1994:423370 BIOSIS  
DN PREV199497436370  
TI Molecular requirements of peptide structure binding to the lipid-A region of bacterial endotoxins.  
AU Velucchi, Massimo; Rustici, Alessandro; **Porro, Massimo**  
CS Biosynth Res. Lab., Zona Industriale, Rapolano Terme, Siena 53040 Italy  
SO Norrby, E. [Editor]; Brown, F. [Editor]; Chanock, R. M. [Editor]; Ginsberg, H. S. [Editor]. Vaccines (Cold Spring Harbor), (1994) Vol. 94, pp. 141-146. Vaccines (Cold Spring Harbor); Modern approaches to new vaccines including prevention of AIDS.  
Publisher: Cold Spring Harbor Laboratory Press 10 Skyline Drive, Plainview, New York 11803, USA.  
Meeting Info.: Eleventh Annual Meeting on Modern Approaches to New Vaccines Cold Spring Harbor, New York, USA September 1993  
ISSN: 0899-4056. ISBN: 0-87969-434-3.  
DT Book; Conference  
LA English

L3 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2001 ACS  
AN 1994:698634 CAPLUS  
DN 121:298634  
TI Molecular requirements of peptide structures binding to the lipid-A region of bacterial endotoxins  
AU Velucchi, Massimo; Rustici, Alessandro; **Porro, Massimo**  
CS BioYnth Res. Lab., Zona Industriale, Siena, 53040, Italy  
SO Vaccines 94: Mod. Approaches New Vaccines Incl. Prev. AIDS, [Annu. Meet.], 11th (1994), Meeting Date 1993, 141-6. Editor(s): Norrby, Erling.  
Publisher: Cold Spring Harbor Lab. Press, Cold Spring Harboy, N.Y.  
CODEN: 60PMAJ  
DT Conference  
LA English  
AB The binding of selected peptides to lipid A of heterologous lipopolysaccharides was assessed and measured by the value of selectivity, which expresses the ratio between the affinity const. value of Polymyxin B and that of each synthetic peptide in competition anal. Both the ref. and the synthetic peptides with a value of .gtoreq.0.75 Rc/h were able to inhibit competitively the lipid A-induced hemorrhagic necrosis in rabbits at doses as high as 75-125 .mu.g/mL of LPS.

L3 ANSWER 13 OF 17 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2  
AN 1993:145833 BIOSIS  
DN PREV199395078633  
TI Molecular mapping and detoxification of the lipid A binding site by synthetic peptides.  
AU Rustici, Alessandro; Velucchi, Massimo; Faggioni, Raffaella; Sironi, Marina; Ghezzi, Pietro; Quataert, Sally; Green, Bruce; **Porro, Massimo**  
(1)  
CS (1) Biosynth Res. Lab., Rapolano Terme, Siena, Italy 53040  
SO Science (Washington D C), (1993) Vol. 259, No. 5093, pp. 361-365.  
ISSN: 0036-8075.  
DT Article  
LA English  
AB Endotoxin (lipopolysaccharide (LPS)), the major antigen of the outer



membrane of Gram-negative **bacteria**, consists of a variable-size carbohydrate chain that is covalently linked to N, O-acylated beta-1, 6-D-glucosamine disaccharide 1,4'-bisphosphate (lipid A). The toxic activity of LPS residues in the lipid A structure. The structural features of synthetic peptides that bind to lipid A with high affinity, detoxify LPS in vitro, and prevent LPS-induced cytokine release and lethality in vivo were defined. The binding thermodynamics were comparable to that of an antigen-antibody reaction. Such synthetic peptides may provide a strategy of prophylaxis and the treatment of LPS-mediated diseases.

L3 ANSWER 14 OF 17 USPATFULL  
AN 92:82892 USPATFULL  
TI Oligosaccharide conjugate vaccines  
IN **Porro, Massimo**, Siena, Italy  
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)  
PI US 5153312 19921006  
AI US 1990-590649 19900928 (7)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Kim, Kay  
LREP Dow, Kenneth J.  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular polysaccharide.

A specific embodiment of the invention provides for vaccines which induce immunity to prevalent serotypes of Streptococcus pneumoniae.

L3 ANSWER 15 OF 17 USPATFULL  
AN 87:84425 USPATFULL  
TI Glycoprotein conjugates having trivalent immunogenic activity  
IN **Porro, Massimo**, Localita' Collanza, Italy  
Costantino, Paolo, Colle Val d'Elsa, Italy  
PA Sclavo S.p.A., Siena, Italy (non-U.S. corporation)  
PI US 4711779 19871208  
AI US 1986-881091 19860702 (6)  
PRAI IT 1985-21451 19850705  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Schain, Howard E.  
LREP Hedman, Gibson, Costigan & Hoare  
CLMN Number of Claims: 12  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 622

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Glycoprotein conjugates having trivalent immunogenic activity obtained

by binding, by a covalent bond, to a protein selected among CRM 197, tetanus toxoid, and pertussis toxin, at least an oligosaccharidic

hapten

derived from the capsular polysaccharide of a gram-positive bacterium and at least an oligosaccharidic hapten derived from the capsular polysaccharide of a gram-negative bacterium, and wherein said oligosaccharidic haptens are previously activated by introducing terminal esters.

L3 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2001 ACS

AN 1987:125868 CAPLUS  
 DN 106:125868  
 TI Prepn. of glycoprotein conjugates having trivalent immunogenic activity  
 as vaccines against bacterial infections  
 IN **Porro, Massimo**; Costantino, Paolo  
 PA Sclavo S.p.A., Italy  
 SO Eur. Pat. Appl., 12 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 208375	A2	19870114	EP 1986-201160	19860702
	EP 208375	A3	19890405		
	EP 208375	B1	19911211		
	R: AT, BE, CH, DE, FR, GB, LI, LU, NL, SE				
	US 4711779	A	19871208	US 1986-881091	19860702
	AT 70187	E	19911215	AT 1986-201160	19860702
	JP 62030726	A2	19870209	JP 1986-156342	19860704
	CA 1272952	A1	19900821	CA 1986-513124	19860704
PRAI	IT 1985-21451		19850705		
	EP 1986-201160		19860702		

AB Glycoprotein conjugates having trivalent immunogenic activity are  
 prepd.

by conjugating a protein (e.g. CRM 197) to oligosaccharidic  
 hapten(s) derived from the capsular polysaccharide of a gram-pos.  
 bacterium and oligosaccharidic hapten(s) derived from the  
 capsular polysaccharide of a gram-neg. bacterium, where the  
 oligosaccharidic haptens are previously activated by introducing terminal  
 esters. Oligosaccharidic haptens were prepd. from the capsular  
 polysaccharides of *S. pneumoniae* type 6A and *N. meningitidis* group C by  
 hydrolysis reaction in pH 3.4 and 5, resp., at 100.degree. in a sealed  
 ampul for 39 h and 8 h, resp. The haptens were activated by introducing  
 primary amino groups into the terminal reducing groups of the haptens,

and  
 converting the amino groups to monofunctional esters in DMS contg.  
 di-succinimidyl ester of adipic acid. The activated haptens were  
 conjugated to CRM 197 protein. The antisera of rabbits injected with the  
 conjugate showed bactericidal activity.

L3 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2001 ACS

AN 1986:205102 CAPLUS

DN 104:205102

TI A molecular model of artificial glycoprotein with predetermined multiple  
 immunodeterminants for gram-positive and gram-negative encapsulated  
**bacteria**

AU **Porro, Massimo**; Costantino, Paolo; Giovannoni, Franco;  
 Pellegrini, Vittoria; Tagliaferri, Lucia; Vannozzi, Francesca; Viti,  
 Stefano

CS Bact. Vaccine Dep., Sclavo SpA, Siena, 53100, Italy

SO Mol. Immunol. (1986), 23(4), 385-91

CODEN: MOIMD5; ISSN: 0161-5890

DT Journal

LA English

AB An artificial mol. was synthesized by covalently linking the  
 oligosaccharide hapten derived from *Streptococcus pneumoniae* type 6A and  
*Neisseria meningitidis* group C capsular polysaccharides to the non-toxic  
 mutant protein CRM197, serol. related to diphtheria toxin. Immunochem.  
 anal., using polyclonal and monoclonal antibodies, showed that the  
 glycoprotein had specific immunodeterminants of the native  
 polysaccharides

and of the carrier protein. The immunol. activity of this hybrid mol.  
 tested in 2 animal models gave evidence for anamnestic induction of serum  
 antibodies specifically directed to the 3 distinct native mols. They

neutralized the toxicity of diphtheria toxin, recognized the polysaccharide capsule of *S. pneumoniae* type 6A and 6B (group 6) strain and killed the *N. meningitidis* group C **bacteria** by complement-mediated bacterial lysis. These findings support the possibility of using in humans a multivalent antigen with immunogenic activity for several epidemiol. significant gram-pos. and gram-neg. encapsulated bacterial strains.

=> d his

(FILE 'HOME' ENTERED AT 12:03:48 ON 09 AUG 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA, LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001  
E PORRO MASSIMO/AU  
E PORRO MASSIMO/AU

L1 40 S E3  
L2 20 S L1 AND BACTERIA  
L3 17 DUP REM L2 (3 DUPLICATES REMOVED)

=> s l1 and gram negative

L4 17 L1 AND GRAM NEGATIVE

=> s l4 and lps

L5 8 L4 AND LPS

=> d bib ab 1-8

L5 ANSWER 1 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS  
AN 2000:173998 BIOSIS  
DN PREV200000173998  
TI Influence of synthetic antiendotoxin peptides on Lipopolysaccharide ( **LPS**) recognition and **LPS**-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.  
AU Iwagaki, Akitaka; Porro, Massimo; Pollack, Matthew (1)  
CS (1) Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814 USA  
SO Infection and Immunity., (March, 2000) Vol. 68, No. 3, pp. 1655-1663. ISSN: 0019-9567.  
DT Article  
LA English  
SL English  
AB Lipopolysaccharides (**LPS**) are proinflammatory bacterial products implicated in the pathogenesis of **gram-negative** sepsis and septic shock. Polymyxin B (PMB), a cyclic, cationic peptide antibiotic, inhibits biological activities of **LPS** through high-affinity binding to the lipid A moiety. Small synthetic peptides have been designed to mimic the primary and secondary structures of PMB to determine structural requirements for binding and detoxification of lipid A and to assess possible therapeutic potential. The purpose of this study was to compare and contrast the endotoxin-neutralizing activities of two synthetic antiendotoxin peptides (SAEP-2 and SAEP-4), PMB, and an **LPS** core-specific monoclonal antibody (MAb), WN1 222-5, based on their abilities to inhibit CD14-mediated target cell uptake of fluorescein isothiocyanate (FITC)-conjugated **LPS**, detected by flow cytometry

and confocal microscopy, and **LPS**-induced production of the proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), as measured by bioassays. PMB and SAEP-4 produced dose-dependent inhibition of FITC-**LPS** uptake by CD14-transfected Chinese hamster ovary fibroblasts (CHO-CD14 cells) and by human peripheral

blood mononuclear cells. The anti-**LPS** MAb, WN1 222-5, also blocked **LPS** uptake by these cells and synergized with PMB and SAEP-4. **LPS**-induced IL-6 release was inhibited by PMB, SAEP-4, and MAb WN1 222-5, and these inhibitory activities were additive or synergistic. **LPS**-induced TNF-alpha release by PBMC was also inhibited by PMB and SAEP-4 alone and in combination with anti-**LPS** MAb. SAEP-2, in contrast, produced comparatively minor decrements in cellular uptake of **LPS** and **LPS**-induced cytokine responses, and did so only in the absence of serum, while a nonsense peptide exerted no discernible inhibitory effect on **LPS** uptake or **LPS**-induced cytokine expression in the presence or absence of serum. Thus, PMB and SAEP-4, like the **LPS**-reactive MAb, WN1 222-5, block proinflammatory activities of **LPS** in part by preventing **LPS** recognition by membrane-bound CD14-expressing target cells. Differences in peptide structure, however, like those exemplified by SAEP-2 and SAEP-4, may differentially affect the endotoxin-neutralizing potency of these peptides despite similar binding activity against lipid A, reflecting possible differences in peptide solubility or peptide regulation of intracellular signal transduction.

L5 ANSWER 2 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS

AN 1993:145833 BIOSIS

DN PREV199395078633

TI Molecular mapping and detoxification of the lipid A binding site by synthetic peptides.

AU Rustici, Alessandro; Velucchi, Massimo; Faggioni, Raffaella; Sironi, Marina; Ghezzi, Pietro; Quataert, Sally; Green, Bruce; Porro, Massimo (1)

CS (1) Biosynth Res. Lab., Rapolano Terme, Siena, Italy 53040

SO Science (Washington D C), (1993) Vol. 259, No. 5093, pp. 361-365. ISSN: 0036-8075.

DT Article

LA English

AB Endotoxin (lipopolysaccharide (**LPS**)), the major antigen of the outer membrane of **Gram-negative** bacteria, consists of a variable-size carbohydrate chain that is covalently linked to N, O-acylated beta-1, 6-D-glucosamine disaccharide 1,4'-bisphosphate (lipid A). The toxic activity of **LPS** residues in the lipid A structure. The structural features of synthetic peptides that bind to lipid A with high affinity, detoxify **LPS** in vitro, and prevent **LPS**-induced cytokine release and lethality in vivo were defined. The binding thermodynamics were comparable to that of an antigen-antibody reaction. Such synthetic peptides may provide a strategy of prophylaxis and the treatment of **LPS**-mediated diseases.

L5 ANSWER 3 OF 8 USPATFULL

AN 1998:138863 USPATFULL

TI Potentiation of antibiotics

IN Porro, Massimo, Siena, Italy  
Varra, Martti, Haartmaninkatu, Finland

PA BiosYnth S.r.l., Italy (non-U.S. corporation)

PI US 5834430 19981110

AI US 1995-456112 19950531 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 45

ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with methods of potentiating an antibiotic. The invention also includes compositions of an antibiotic and a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with  
a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer  
with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer  
with a minimum value of 2. The compositions have potentiated antibiotic activity.

L5 ANSWER 4 OF 8 USPATFULL

AN 97:66100 USPATFULL

TI Peptides for neutralizing the toxicity of Lipid A

IN Porro, Massimo, Siena, Italy

PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5652211 19970729

AI US 1993-97830 19930726 (8)

RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned, said Ser. No. US -49871 which is a continuation of Ser. No. US -658744

DT Utility

FS Granted

EXNAM Primary Examiner: Russell, Jeffrey E.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 39

ECL Exemplary Claim: 36,38

DRWN No Drawings

LN.CNT 683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with a peptide composition which includes a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with  
a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer  
with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine,

Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L5 ANSWER 5 OF 8 USPATFULL

AN 96:120869 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN **Porro, Massimo**, Siena, Italy

PA Biosynth s.r.l., Siena, Italy (non-U.S. corporation)

PI US 5589459 19961231

AI US 1994-280397 19940726 (8)

RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,

Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Davenport, Avis M.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently

H

or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an

amino

acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L5 ANSWER 6 OF 8 USPATFULL

AN 94:106884 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN **Porro, Massimo**, Siena, Italy

PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5371186 19941206

AI US 1992-819893 19920116 (7)

DCD 20111025

RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel peptides of the formula R.sub.1 --(A-B-C).sub.n --R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the

prevention

and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L5 ANSWER 7 OF 8 USPATFULL  
AN 94:93312 USPATFULL  
TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock  
IN Porro, Massimo, Siena, Italy  
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5358933 19941025  
AI US 1993-49871 19930419 (8)  
RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.  
LREP Hedman, Gibson & Costigan  
CLMN Number of Claims: 16  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 483  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel peptides are disclosed which are based on the formula:

R.sub.1 (Lys-Phe-Leu).sub.n --R

wherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:84285 CAPLUS  
DN 132:136410  
TI Vaccines for prevention of **gram-negative** bacterial infections and endotoxin-related diseases  
IN Porro, Massimo  
PA Biosynth S.R.L., Italy  
SO Eur. Pat. Appl., 40 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 976402	A2	20000202	EP 1999-202476	19990727

PI R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO  
PRAI US 1998-124280 19980729  
AB A vaccine is disclosed which is useful for protecting a host from Gram neg. infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepd. by combining **LPS** free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)<sub>n</sub> wherein A is Lysine or Arginine and n is an integer with a min. value of 7; (b) (AB)<sub>m</sub> wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a min. value of 3; and (c) (ABC)<sub>p</sub> wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a min. value of 2.

=> d clm 4 5 6 7

L5 ANSWER 4 OF 8 USPATFULL

CLM What is claimed is:

1. A peptide consisting of the formula: (Lys-Phe).sub.5 (SEQ ID NO: 5).
- (SEQ 2. A peptide consisting of the formula: Lys-Phe-Leu-Lys-Lys-Thr-Leu  
ID NO: 6).
- ID 3. A peptide consisting of the formula: (Lys-Phe-Phe).sub.3 -Lys (SEQ  
NO: 10).
4. A peptide consisting of the formula: (Lys-Leu-Leu).sub.3 (SEQ ID NO:  
11).
- (SEQ 5. A peptide consisting of the formula: (Lys).sub.6 (Phe-Lys).sub.2  
ID NO: 12).
6. A peptide consisting of the formula: ##STR13##
7. A peptide consisting of the formula: ##STR14##
8. A peptide consisting of the formula: ##STR15##
9. A peptide consisting of the formula: ##STR16##
10. A peptide consisting of the formula: ##STR17##
11. A peptide consisting of the formula: ##STR18##
12. A peptide consisting of the formula: ##STR19##
13. A peptide consisting of the formula:  
Lys-Ser-Leu-Ser-Leu-Lys-Arg-Leu-  
Thr-Tyr-Arg (SEQ ID NO:22).
14. A peptide consisting of the formula:  
Lys-Val-Arg-Lys-Ser-Phe-Phe-Lys-  
Leu (SEQ ID NO: 23).
15. A peptide consisting of the formula:  
Phe-Leu-Lys-Pro-Gly-Lys-Val-Lys-  
Val (SEQ ID NO: 24).
16. A peptide consisting of the formula:  
Lys-Glu-Leu-Lys-Arg-Ile-Lys-Ile  
(SEQ ID NO: 25).
17. A peptide consisting of the formula: ##STR20##
18. A peptide composition which includes a pharmaceutical carrier and a  
peptide of claim 1.
19. A peptide composition which includes a pharmaceutical carrier and a  
peptide of claim 2.
20. A peptide composition which includes a pharmaceutical carrier and a  
peptide of claim 3.
21. A peptide composition which includes a pharmaceutical carrier and a



peptide of claim 4.

22. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 5.

23. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 6.

24. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 7.

25. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 8.

26. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 9.

27. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 10.

28. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 11.

29. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 12.

30. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 13.

31. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 14.

32. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 15.

33. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 16.

34. A peptide composition which includes a pharmaceutical carrier and a peptide consisting of the formula: Lys-Arg-Leu-Lys-Trp-Lys-Tyr-Lys-Gly-Lys-Phe (SEQ ID NO:28).

35. A peptide composition which includes a pharmaceutical carrier and a peptide of claim 17.

36. A peptide composition which comprises a peptide of the formula (Lys).sub.30 (SEQ ID NO: 2) and a pharmaceutical carrier.

37. A peptide composition which comprises a peptide of the formula (Lys).sub.434 (SEQ ID NO: 3) and a pharmaceutical carrier.

38. A method of treating or preventing septic shock which comprises administering to a mammal an effective amount of the peptide composition of claim 36.

39. A method of treating or preventing septic shock which comprises administering to a mammal an effective amount of the peptide composition of claim 37.

L5 ANSWER 5 OF 8 USPATFULL

CLM What is claimed is:

1. A method for the removal of endotoxin from human and animal blood

sera which comprises contacting said blood or sera with a peptide of which is a monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula:  $R_{sub.1}-(A-B-C)_{sub.n}-R$  (I) wherein  $R_{sub.1}$  and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from 1-100, in an amount which is effective for the removal of endotoxin from said blood or sera.

2. A method for the detoxification of bacterial endotoxins which comprises treating the affected host with an amount of a peptide which is a monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula:  $R_{sub.1}-(A-B-C)_{sub.n}-R$  (I) wherein  $R_{sub.1}$  and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from 1-100 which is effective to detoxify any endotoxin which is in an affected host.

3. A method for the detoxification of a bacterial endotoxin which comprises contacting the bacterial endotoxin or a fluid containing the endotoxin with an amount of a peptide, which is effective for detoxification of said bacterial endotoxin, said peptide being a monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula:  $R_{sub.1}-(A-B-C)_{sub.n}-R$  (I) wherein  $R_{sub.1}$  and R are independently H or an amino acid residue or a fatty acid residue.; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from 1-100.

4. A method for preventing contamination of a product with endotoxin, said method comprising adding to a product an amount of a peptide which is a monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula:  $R_{sub.1}-(A-B-C)_{sub.n}-R$  (I) wherein  $R_{sub.1}$  and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from 1-100 which is effective to neutralize any endotoxin which is subsequently elaborated by bacterial growth.

5. A method as defined in claim 2 wherein the peptide is of the formula:  
##STR3##

6. A method as defined in claim 2 wherein the peptide is of the formula:  
##STR4##

7. A method as defined in, claim 2 wherein the peptide is of the formula: Lys-Phe-Leu-Lys-Lys-Thr  
(SEQ  
ID NO:3).

8. A method as defined in claim 2 wherein the peptide is of the formula:  
##STR5##

9. A method as defined in claim 2 wherein the peptide is of the formula:

##STR6##

10. A method as defined in claim 2 wherein the peptide is of the formula: ##STR7##

11. A method as defined in claim 2 wherein the peptide is of the formula: Ile--Lys--Thr--Lys--Lys--Phe--Leu--Lys--Lys--Thr

(SEQ

ID NO:7).

12. A method as defined in claim 2 wherein the peptide is of the formula: Ile--Lys--Phe--Leu--Lys--Phe--Leu--Lys--Phe--Leu--Lys

(SEQ

ID NO:8).

13. A method as defined in claim 2 wherein the peptide is of the formula: Lys--Phe--Leu--Lys--Phe--Leu--Lys

(SEQ

ID NO:9).

14. A method as defined in claim 2 wherein the peptide is of the formula: Arg-Tyr-Val-Arg-Tyr-Val-Arg-Tyr-Val

(SEQ

ID NO:10).

L5 ANSWER 6 OF 8 USPATFULL

CLM What is claimed is:

1. A monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula: R.sub.1-(A-B-C).sub.n-R

(I) wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an amino acid selected from the group consisting of Phe, Tyr and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of from

1-100.

2. A monomeric, linear polymeric, cyclic monomeric or cyclic polymeric peptide of the formula: R.sub.1 (Lys-Phe-Leu).sub.n-R

(II) wherein n is a integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue.

3. A peptide which is of the formula: Lys-Phe-Leu-Lys-Phe-Leu-Lys (SEQ ID NO:9).

4. A peptide which is of the formula: Arg-Tyr-Val-Arg-Tyr-Val-Arg-Tyr-Val (SEQ ID NO:10).

5. A pharmaceutical composition which comprises a peptide of claim 1 and a pharmaceutical carrier.

6. A pharmaceutical composition which comprises a peptide of claim 3 and a pharmaceutical carrier.

7. A pharmaceutical composition which comprises a peptide of claim 4 and a pharmaceutical carrier.

8. Peptide sequences which are the retro-oriented amino acid sequences of claim 1.

9. Peptide sequences which are the enantiomer amino acid sequences (all-D amino acid in the sequence) of the peptides of claim 1.
10. Peptide sequences which are the diastereomer amino acid sequences of the peptides of claim 1 (-D and -L amino acid in the same sequence).
11. Peptide sequences in which the amino acids are inverted with respect to their original position in the sequence of the peptides of claim 1.

L5 ANSWER 7 OF 8 USPATFULL

CLM What is claimed is:

1. A peptide of the formula: Cys-Lys-Phe-Leu-Lys-Lys-Cys S-----S (SEQ ID NO:1)
  2. A peptide according to which is of the formula: Lys-Thr-Lys-Cys-Lys-Phe-Leu-Lys-Lys-Cys S-----S (SEQ ID NO:2)
  3. A peptide which is of the formula: Lys-Phe-Leu-Lys-Lys-Thr (SEQ ID NO:3)
  4. A peptide which is of the formula: Cys-Lys-Lys-Leu-Phe-Lys-Cys-Lys-Thr-Lys S-----S (SEQ ID NO:4)
  5. A peptide which is of the formula: Cys-Lys-Lys-Leu-Phe-Lys-Cys-Lys-Thr S-----S (SEQ ID NO:5)
  6. A peptide which is of the formula: Ile-Lys-Thr-Lys-Cys-Lys-Phe-Leu-Lys-Lys-Cys S-----S (SEQ ID NO:6)
  7. A peptide which is of the formula: Ile-Lys-Thr-Lys-Lys-Phe-Leu-Lys-Lys-Thr (SEQ ID NO:7)
  8. A peptide which is of the formula: Ile-Lys-Phe-Leu-Lys-Phe-Leu-Lys-Phe-Leu-Lys (SEQ ID NO:8)
9. A pharmaceutical composition which comprises a peptide of claim 1 and a pharmaceutical carrier.
10. A pharmaceutical composition which comprises a peptide of claim 2 and a pharmaceutical carrier.
11. A pharmaceutical composition which comprises a peptide of claim 3 and a pharmaceutical carrier.
12. A pharmaceutical composition which comprises a peptide of claim 4 and a pharmaceutical carrier.
13. A pharmaceutical composition which comprises a peptide of claim 5 and a pharmaceutical carrier.
14. A pharmaceutical composition which comprises a peptide of claim 6 and a pharmaceutical carrier.
15. A pharmaceutical composition which comprises a peptide of claim 7 and a pharmaceutical carrier.
16. A pharmaceutical composition which comprises a peptide of claim 8 and a pharmaceutical carrier.

=> d his

(FILE 'HOME' ENTERED AT 12:03:48 ON 09 AUG 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS,  
AGRICOLA,  
LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001  
E PORRO MASSIMO/AU  
E PORRO MASSIMO/AU

L1 40 S E3  
L2 20 S L1 AND BACTERIA  
L3 17 DUP REM L2 (3 DUPLICATES REMOVED)  
L4 17 S L1 AND GRAM NEGATIVE  
L5 8 S L4 AND LPS

=> s l1 and lps

L6 14 L1 AND LPS

=> dup rem l6

PROCESSING COMPLETED FOR L6  
L7 12 DUP REM L6 (2 DUPLICATES REMOVED)

=> d bib ab 1-12

L7 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:84285 CAPLUS  
DN 132:136410  
TI Vaccines for prevention of gram-negative bacterial infections and  
endotoxin-related diseases  
IN **Porro, Massimo**  
PA Biosynth S.R.L., Italy  
SO Eur. Pat. Appl., 40 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 976402	A2	20000202	EP 1999-202476	19990727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-124280		19980729		
AB	A vaccine is disclosed which is useful for protecting a host from Gram neg. infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prep'd. by combining <b>LPS</b> free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A) <sub>n</sub> wherein A is Lysine or Arginine and n is an integer with a min. value of 7; (b) (AB) <sub>m</sub> wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a min. value of 3; and (c) (ABC) <sub>p</sub> wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a min. value of 2.				

L7 ANSWER 2 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 1  
AN 2000:173998 BIOSIS  
DN PREV200000173998

TI Influence of synthetic antiendotoxin peptides on Lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14.  
 AU Iwagaki, Akitaka; Porro, Massimo; Pollack, Matthew (1)  
 CS (1) Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814 USA  
 SO Infection and Immunity., (March, 2000) Vol. 68, No. 3, pp. 1655-1663. ISSN: 0019-9567.  
 DT Article  
 LA English  
 SL English  
 AB Lipopolysaccharides (LPS) are proinflammatory bacterial products implicated in the pathogenesis of gram-negative sepsis and septic shock. Polymyxin B (PMB), a cyclic, cationic peptide antibiotic, inhibits biological activities of LPS through high-affinity binding to the lipid A moiety. Small synthetic peptides have been designed to mimic the primary and secondary structures of PMB to determine structural requirements for binding and detoxification of lipid A and to assess possible therapeutic potential. The purpose of this study was to compare and contrast the endotoxin-neutralizing activities of two synthetic antiendotoxin peptides (SAEP-2 and SAEP-4), PMB, and an LPS core-specific monoclonal antibody (MAb), WN1 222-5, based on their abilities to inhibit CD14-mediated target cell uptake of fluorescein isothiocyanate (FITC)-conjugated LPS, detected by flow cytometry and confocal microscopy, and LPS-induced production of the proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha), as measured by bioassays. PMB and SAEP-4 produced dose-dependent inhibition of FITC-LPS uptake by CD14-transfected Chinese hamster ovary fibroblasts (CHO-CD14 cells) and by human peripheral blood mononuclear cells. The anti-LPS MAb, WN1 222-5, also blocked LPS uptake by these cells and synergized with PMB and SAEP-4. LPS-induced IL-6 release was inhibited by PMB, SAEP-4, and MAb WN1 222-5, and these inhibitory activities were additive or synergistic. LPS-induced TNF-alpha release by PBMC was also inhibited by PMB and SAEP-4 alone and in combination with anti-LPS MAb. SAEP-2, in contrast, produced comparatively minor decrements in cellular uptake of LPS and LPS-induced cytokine responses, and did so only in the absence of serum, while a nonsense peptide exerted no discernible inhibitory effect on LPS uptake or LPS-induced cytokine expression in the presence or absence of serum. Thus, PMB and SAEP-4, like the LPS-reactive MAb, WN1 222-5, block proinflammatory activities of LPS in part by preventing LPS recognition by membrane-bound CD14-expressing target cells. Differences in peptide structure, however, like those exemplified by SAEP-2 and SAEP-4, may differentially affect the endotoxin-neutralizing potency of these peptides despite similar binding activity against lipid A, reflecting possible differences in peptide solubility or peptide regulation of intracellular signal transduction.

L7 ANSWER 3 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS  
 AN 2000:532911 BIOSIS  
 DN PREV200000532911  
 TI Effects of synthetic anti-endotoxin peptides (SAEP) on calmodulin.  
 AU Rustici, Alessandro (1); Velucchi, Massimo (1); Porro, Massimo (1)  
 CS (1) BiosYnth Srl, 53040, Rapolano Terme, Siena Italy  
 SO Journal of Endotoxin Research, (2000) Vol. 6, No. 2, pp. 133-134. print. Meeting Info.: 6th Conference of the International Endotoxin Society Paris, France August 24-27, 2000 ISSN: 0968-0519.  
 DT Conference  
 LA English  
 SL English

L7 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:605922 CAPLUS  
DN 132:20140  
TI LPS/lipid A-binding synthetic peptides  
AU Porro, Massimo  
CS Biosynth Research Laboratories, Siena, Italy  
SO Endotoxin Health Dis. (1999), 403-411. Editor(s): Brade, Helmut.  
Publisher: Marcel Dekker, New York, N. Y.  
CODEN: 68EJA9  
DT Conference; General Review  
LA English  
AB A review with 47 refs. on polymyxin B and its peptide analogs binding to lipid A.  
RE.CNT 47

RE  
(3) Bhattacharjya, S; Biopolymers 1997, V41(3), P251 CAPLUS  
(4) Cady, A; Infect Immun 1989, V57, P396 CAPLUS  
(5) Cho, H; J Exp Med 1992, V176, P599 CAPLUS  
(6) Christensen, H; J Biol Chem 1966, V241, P5542 CAPLUS  
(7) Craig, W; Infect Immun 1974, V10, P287 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 12 USPATFULL  
AN 1998:138863 USPATFULL  
TI Potentiation of antibiotics  
IN Porro, Massimo, Siena, Italy  
Varra, Martti, Haartmaninkatu, Finland  
PA Biosynth S.r.l., Italy (non-U.S. corporation)  
PI US 5834430 19981110  
AI US 1995-456112 19950531 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Harle, Jennifer  
LREP Hedman, Gibson & Costigan, P.C.  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with methods of potentiating an antibiotic. The invention also includes compositions of an antibiotic and a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with  
a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer  
with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer  
with a minimum value of 2. The compositions have potentiated antibiotic activity.

L7 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2001 ACS

AN 1998:412126 CAPLUS  
DN 129:188002  
TI Natural and synthetic polypeptides that recognize the conserved lipid A binding site of lipopolysaccharides  
AU **Porro, Massimo**; Rustici, Alessandro; Velucchi, Massimo; Agnello, Davide; Villa, Pia; Ghezzi, Pietro  
CS Biosynth Research Laboratories, Siena, 53040, Italy  
SO Prog. Clin. Biol. Res. (1998), 397 (Endotoxin and Sepsis), 315-325  
CODEN: PCBRD2; ISSN: 0361-7742  
PB Wiley-Liss, Inc.  
DT Journal; General Review  
LA English  
AB A review with .apprx.25 refs. The authors review their work on various natural and synthetic polypeptides that recognize the conserved lipid A binding site of lipopolysaccharides and in particular talk about in vivo and in vitro assays demonstrating the ability of nociceptin to neutralize lipopolysaccharide activity. The results suggest that nociceptin might be a potential target of **LPS** in the central and peripheral nervous system. Its capability to interact with **LPS**, through lipid A, might work as a recognition system alerting the host's defenses on the basis of an imbalance in the equil. nociceptin/nociceptor, therefore serving as a physiol. defense against the early biol. effects which follow an **LPS** insult.

L7 ANSWER 7 OF 12 USPATFULL  
AN 97:66100 USPATFULL  
TI Peptides for neutralizing the toxicity of Lipid A  
IN **Porro, Massimo**, Siena, Italy  
PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)  
PI US 5652211 19970729  
AI US 1993-97830 19930726 (8)  
RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned, said Ser. No. US -49871 which is a continuation of Ser. No. US -658744  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Russell, Jeffrey E.  
LREP Hedman, Gibson & Costigan, P.C.  
CLMN Number of Claims: 39  
ECL Exemplary Claim: 36,38  
DRWN No Drawings  
LN.CNT 683  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with a peptide composition which includes a peptide having units of the formula:

(a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7.

(b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine,



Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L7 ANSWER 8 OF 12 USPATFULL

AN 96:120869 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN **Porro, Massimo**, Siena, Italy

PA Biosynth s.r.l., Siena, Italy (non-U.S. corporation)

PI US 5589459 19961231

AI US 1994-280397 19940726 (8)

RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,

Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Davenport, Avis M.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of using peptides of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently

H

or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and Arg; B is an

amino

acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of products with endotoxin.

L7 ANSWER 9 OF 12 USPATFULL

AN 94:106884 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN **Porro, Massimo**, Siena, Italy

PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5371186 19941206

AI US 1992-819893 19920116 (7)

DCD 20111025

RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel peptides of the formula R.sub.1 --(A-B-C).sub.n --R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the

prevention

and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L7 ANSWER 10 OF 12 USPATFULL

AN 94:93312 USPATFULL

TI Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN **Porro, Massimo**, Siena, Italy

PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5358933 19941025

AI US 1993-49871 19930419 (8)

RLI Continuation of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Marshall, S. G.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel peptides are disclosed which are based on the formula:

R.sub.1 (Lys-Phe-Leu).sub.n --R

wherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.

L7 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2001 ACS

AN 1994:698634 CAPLUS

DN 121:298634

TI Molecular requirements of peptide structures binding to the lipid-A region

of bacterial endotoxins

AU Velucchi, Massimo; Rustici, Alessandro; **Porro, Massimo**

CS BioYnth Res. Lab., Zona Industriale, Siena, 53040, Italy

SO Vaccines 94: Mod. Approaches New Vaccines Incl. Prev. AIDS, [Annu. Meet.], 11th (1994), Meeting Date 1993, 141-6. Editor(s): Norrby,

Erling.

Publisher: Cold Spring Harbor Lab. Press, Cold Spring Harboy, N.Y.

CODEN: 60PMAJ

DT Conference

LA English

AB The binding of selected peptides to lipid A of heterologous lipopolysaccharides was assessed and measured by the value of

selectivity,

which expresses the ratio between the affinity const. value of Polymyxin

B

and that of each synthetic peptide in competition anal. Both the ref.

and

the synthetic peptides with a value of .gtoreq.0.75 Rc/h were able to inhibit competitively the lipid A-induced hemorrhagic necrosis in rabbits at doses as high as 75-125 .mu.g/mL of **LPS**.

L7 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 2

AN 1993:145833 BIOSIS

DN PREV199395078633

TI Molecular mapping and detoxification of the lipid A binding site by synthetic peptides.

AU Rustici, Alessandro; Velucchi, Massimo; Faggioni, Raffaella; Sironi, Marina; Ghezzi, Pietro; Quataert, Sally; Green, Bruce; **Porro, Massimo**

(1)  
CS (1) Biosynth Res. Lab., Rapolano Terme, Siena, Italy 53040  
SO Science (Washington D C), (1993) Vol. 259, No. 5093, pp. 361-365.  
ISSN: 0036-8075.  
DT Article  
LA English  
AB Endotoxin (lipopolysaccharide (LPS)), the major antigen of the outer membrane of Gram-negative bacteria, consists of a variable-size carbohydrate chain that is covalently linked to N, O-acylated beta-1, 6-D-glucosamine disaccharide 1,4'-bisphosphate (lipid A). The toxic activity of LPS residues in the lipid A structure. The structural features of synthetic peptides that bind to lipid A with high affinity, detoxify LPS in vitro, and prevent LPS-induced cytokine release and lethality in vivo were defined. The binding thermodynamics were comparable to that of an antigen-antibody reaction. Such synthetic peptides may provide a strategy of prophylaxis and the treatment of LPS-mediated diseases.

=> s lps and peptid?

L8 6792 LPS AND PEPTID?

=> s l8 and stoichiometric

L9 93 L8 AND STOICHIOMETRIC

=> dup rem l9

PROCESSING COMPLETED FOR L9

L10 88 DUP REM L9 (5 DUPLICATES REMOVED)

=> s l10 and (gram negative or bacteria)

10 FILES SEARCHED...

L11 65 L10 AND (GRAM NEGATIVE OR BACTERIA)

=> s l11 and vaccin?

L12 14 L11 AND VACCIN?

=> d bib ab 1-14

L12 ANSWER 1 OF 14 USPATFULL

AN 2001:116819 USPATFULL

TI Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription

IN Morgan, Antony R., late of Edmonton, Canada deceased  
Morgan, Robert Charles, Toronto, Canada executor  
Severini, Alberto, Edmonton, Canada

PA DNAB Diagnostics, Inc., Edmonton, Canada (non-U.S. corporation)

PI US 6265213 B1 20010724

AI US 2000-593323 20000613 (9)

RLI Division of Ser. No. US 1999-344300, filed on 24 Jun 1999

DT Utility

FS GRANTED

EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Wilder, Cynthia

LREP Medlen & Carroll, LLP

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 18 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 2418

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides plasmids that are useful in detecting and determining the DNA-binding activity of sequence-specific DNA-binding molecules. The invention further provides plasmids that are useful in detecting and determining the activity of RNA polymerases in initiating transcription. In particular, the invention relates to plasmids that contain unique restriction sites and cognate nucleotide recognition sequences for sequence-specific DNA-binding molecules. Also provided are methods for using the plasmids disclosed herein.

L12 ANSWER 2 OF 14 USPATFULL

AN 2000:131642 USPATFULL

TI Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having an endosome disruption

agent

IN Boutin, Raymond H., Thornton, PA, United States

PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)

PI US 6127170 20001003

WO 9610038 19960404

AI US 1997-809397 19970321 (8)

WO 1995-US12502 19950928

19970321 PCT 371 date

19970321 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-314060, filed on 28 Sep 1994, now patented, Pat. No. US 5837533, issued on 17 Nov 1998

DT Utility

FS Granted

EXNAM Primary Examiner: Crouch, Deborah

LREP Howson and Howson

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4293

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided. The complex is comprised of

A) said nucleic acid composition and B) a transfer moiety comprising 1)

one or more cationic polyamines bound to said nucleic acid composition, 2) one or more endosome membrane disrupting components attached to at

least one nitrogen of the polyamine and 3) one or more receptor specific binding components.

L12 ANSWER 3 OF 14 USPATFULL

AN 1998:143936 USPATFULL

TI Complexes comprising a nucleic acid bound to a cationic polyamine having

an endosome disruption agent

IN Boutin, Raymond H., Thornton, PA, United States

PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)

PI US 5837533 19981117

AI US 1994-314060 19940928 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Crouch, Deborah

LREP Howson and Howson

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3984

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided which comprises in any functional combination: A) said nucleic acid composition; and B) a transfer moiety comprising 1) one or more cationic polyamine components bound to said nucleic acid composition, each comprising from three to twelve nitrogen atoms; 2) one or more endosome membrane disruption promoting components attached to at least one nitrogen atom of at least one of said polyamine components, through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group, comprising a) at least one lipophilic long chain alkyl group, b) a fusogenic **peptide** comprising spike glycoproteins of enveloped animal viruses, or c) cholic acid or cholesteryl or derivatives; and optionally 3) one or more receptor specific binding components which are ligands for natural receptors of said target cell, attached through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group to either i) a further nitrogen atom of at least one of said polyamine components to which said one or more endosome membrane disruption promoting components is attached, or ii) a nitrogen atom of at least one further polyamine component which does not have attached thereto any endosome membrane disruption promoting component. Also provided are the transfer moiety alone, or in combination with the nucleic acid composition as a self-assembling combination, and the use of these compositions in methods for transferring nucleic acid compositions to cells or to cells of individuals, for immunizing individuals against a pathogen or disease, and for treating an individual with a disease.

L12 ANSWER 4 OF 14 USPATFULL

AN 97:66100 USPATFULL

TI **Peptides** for neutralizing the toxicity of Lipid A

IN Porro, Massimo, Siena, Italy

PA BiosYnth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5652211 19970729

AI US 1993-97830 19930726 (8)

RLI Continuation-in-part of Ser. No. US 1993-49871, filed on 19 Apr 1993, now patented, Pat. No. US 5358933 And Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented, Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned, said Ser. No. US -49871 which is a continuation of Ser. No. US -658744

DT Utility

FS Granted

EXNAM Primary Examiner: Russell, Jeffrey E.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 39

ECL Exemplary Claim: 36,38

DRWN No Drawings

LN.CNT 683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with a **peptide** composition which includes a **peptide** having units of the formula:

a (a) (A).sub.n wherein A is Lysine or Arginine and n is an integer with minimum value of 7.

with (b) (AB).sub.m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer a minimum value of 3; and

(c) (ABC).sub.p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or

different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2. The compositions of the invention bind Lipid-A of endotoxins.

L12 ANSWER 5 OF 14 USPATFULL

AN 96:120869 USPATFULL

TI Synthetic **peptides** for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA BiosYnth s.r.l., Siena, Italy (non-U.S. corporation)

PI US 5589459 19961231

AI US 1994-280397 19940726 (8)

RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,

Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Davenport, Avis M.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of using **peptides** of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and

Arg;

B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The **peptides** are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of

products

with endotoxin.

L12 ANSWER 6 OF 14 USPATFULL

AN 94:106884 USPATFULL

TI Synthetic **peptides** for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5371186 19941206

AI US 1992-819893 19920116 (7)

DCD 20111025

RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel **peptides** of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or

an

amino acid residue or a fatty acid residue; A is an amino acid residue

selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The **peptides** are used inter alia for the prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L12 ANSWER 7 OF 14 USPATFULL

AN 93:107024 USPATFULL

TI Method of inhibiting the activity of leukocyte derived cytokines

IN Mandell, Gerald L., Earlysville, VA, United States

Sullivan, Gail W., Charlottesville, VA, United States

Novick, William J., Lebanon, NJ, United States

PA Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ, United States  
(U.S. corporation)

University of Virginia Alumni Patents Foundation, Charlottesville, VA,  
United States (U.S. corporation)

PI US 5272153 19931221

AI US 1992-908929 19920702 (7)

DCD 20080615

RLI Continuation of Ser. No. US 1991-700522, filed on 15 May 1991, now  
abandoned which is a continuation of Ser. No. US 1990-622138, filed on

5

Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of  
Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a  
continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now  
abandoned which is a continuation of Ser. No. US 1986-947905, filed on  
31 Dec 1986, now abandoned And a continuation of Ser. No. US  
1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271

DT Utility

FS Granted

EXNAM Primary Examiner: Nutter, Nathan M.

LREP Finnegan, Henderson, Farabow, Garrett & Dunner

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A family of compounds effective in inhibiting interleukin-1 (IL-1)  
activity, tumor necrosis factor (TNF) activity, and the activity of  
other leukocyte derived cytokines is comprised of 7-(oxoalkyl)  
1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and  
R.sub.2 are the same or different and are selected from the group  
consisting of straight-chain or branched alkyl radicals with 2 to 6  
carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A  
represents a hydrocarbon radical with up to 4 carbon atoms which can be  
substituted by a methyl group. Another family of effective compounds is  
identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines  
in mammals is implicated in alleviation of a wide variety of disease  
conditions.

L12 ANSWER 8 OF 14 USPATFULL

AN 93:22715 USPATFULL

TI Method of inhibiting the activity of leukocyte derived cytokines

IN Mandell, Gerald L., Earlysville, VA, United States

Sullivan, Gail W., Charlottesville, VA, United States

Novick, William J., Lebanon, NJ, United States

PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States  
(U.S. corporation)

University of Virginia Alumni Patents Foundation, Charlottesville, VA,  
United States (U.S. corporation)

PI US 5196430 19930323

AI US 1991-762200 19910918 (7)

DCD 20071023

RLI Division of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented,

Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned which is a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271 which is a continuation-in-part of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned

DT Utility  
FS Granted  
EXNAM Primary Examiner: Nutter, Nathan M.  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner  
CLMN Number of Claims: 49  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 1535

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branch alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L12 ANSWER 9 OF 14 USPATFULL

AN 93:22714 USPATFULL  
TI Method of inhibiting the activity of leukocyte derived cytokines  
IN Mandell, Gerald L., North Garden, VA, United States  
Sullivan, Gail W., Charlottesville, VA, United States  
Novick, William J., Lebanon, NJ, United States  
PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States  
(U.S. corporation)  
University of VA Alumni Patents Foundation, Charlottesville, VA, United States (U.S. corporation)  
PI US 5196429 19930323  
AI US 1991-738096 19910730 (7)  
RLI Continuation of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a continuation

of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned And a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271 which is a continuation-in-part of Ser. No. US 1986-947905, filed on 31 Dec 1986

DT Utility  
FS Granted  
EXNAM Primary Examiner: Nutter, Nathan M.  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 1344

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and



R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L12 ANSWER 10 OF 14 USPATFULL

AN 89:14777 USPATFULL

TI Method for reducing bacterial endotoxin contamination in solutions of macromolecules

IN Karplus, Thomas E., Sydney, Australia

Ulevitch, Richard J., Del Mar, CA, United States

Wilson, Curtis B., San Diego, CA, United States

PA Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)

PI US 4808314 19890228

AI US 1987-98299 19870918 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Sever, Frank

LREP Dressler, Goldsmith, Shore, Sutker & Milnamow, Ltd.

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention contemplates a method of reducing a bacterial endotoxin contaminant in a biologically useful macromolecule. AN

aqueous

medium containing an endotoxin-contaminated macromolecule is admixed with a dialyzable surfactant, and the admixture so formed is contacted with an endotoxin sorbant to form a solid-liquid phase admixture. The contacting is maintained until the endotoxin is bound to the sorbant. The surfactant is dialyzed out of the aqueous liquid phase at a time no earlier than the maintenance step. The liquid phase containing the macromolecule is separated and recovered.

L12 ANSWER 11 OF 14 USPATFULL

AN 83:11238 USPATFULL

TI Immunologically active dipeptidyl saccharides and methods of preparation

IN Durette, Philippe L., New Providence, NJ, United States

Shen, Tsung-Ying, Westfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4377570 19830322

AI US 1980-193777 19801003 (6)

RLI Division of Ser. No. US 1979-7108, filed on 29 Jan 1979, now patented, Pat. No. US 4256735

DT Utility

FS Granted

EXNAM Primary Examiner: Hazel, Blondel

LREP Perrella, Donald J., Pfeiffer, Hesna J.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1,2

DRWN No Drawings

LN.CNT 1516

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;

R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;

R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;

R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);

R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,

R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or substituted benzyl;

R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;

provided that when R.sub.3 is lower alkyl, the stereochemistry at asymmetric center I can be either D or L, but that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, the stereochemistry at I cannot be D;

when R.sub.7 is not H, the stereochemistry at asymmetric center II is either L or D; and

the stereochemistry at asymmetric center III is D.

These compounds possess immunostimulatory properties.

L12 ANSWER 12 OF 14 USPATFULL

AN 83:1781 USPATFULL

TI Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation

IN Shen, Tsung-Ying, Westfield, NJ, United States

Durette, Philippe L., New Providence, NJ, United States

Dorn, Jr., Conrad P., Plainfield, NJ, United States

Doherty, James B., New Milford, NJ, United States

Dean, Richard T., Fanwood, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4368190 19830111

AI US 1980-141227 19800417 (6)

DT Utility

FS Granted

EXNAM Primary Examiner: Hazel, Blondel

LREP Perrella, Donald J., Speer, Raymond M., Pfeiffer, Hesna J.

CLMN Number of Claims: 34

ECL Exemplary Claim: 1,33,34

DRWN No Drawings

LN.CNT 1240

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immunologically active compounds of the formula: ##STR1## wherein:  
R.sub.1 is C.sub.1-7 alkyl; substituted C.sub.1-7 alkyl; phenyl; or substituted phenyl;

R.sub.2 is hydrogen; C.sub.1-7 alkyl; substituted C.sub.1-7 alkyl; phenyl; substituted phenyl; phenyl C.sub.1-4 alkyl; or substituted phenyl C.sub.1-4 alkyl;

R.sub.3 and R.sub.4 may be the same or different and are each independently hydrogen, provided that R.sub.3 and R.sub.4 may not both be hydrogen; or ##STR2## where X is --O--; --S--; or ##STR3## R.sub.10 is hydrogen; C.sub.1-30 alkyl; C.sub.2-30 alkenyl; C.sub.1-30 alkoxy; phenyl; C.sub.1-20 alkylsulfonyl; or cholesteryl;

0 R.sub.11, R.sub.12, R.sub.13, R.sub.14, and R.sub.15 may be the same or different and are each independently hydrogen; C.sub.1-20 alkyl; C.sub.1-20 alkylcarbonyloxy; amino; benzyl; C.sub.1-20 alkoxyethyl; C.sub.1-20 alkylamido; or ##STR4## r is 0 or 1; s is 0 or 1; and t is to 20; provided that s may only be 0 when both r and t are greater than 0 or when r is 0 and R.sub.10 is amino; phenyl; substituted phenyl; 1-adamantyl; or heterocycle selected from the group consisting of 2- or 3-furyl, 2- or 3- thienyl, 2- or 3- pyrrolidinyl, 2-, 3- or 4- pyridyl, and 1-tetrazolyl, said heterocycle optionally substituted with C.sub.1-20 alkylcarbonyl; and where R.sub.3 or R.sub.4 is other than hydrogen, the other of R.sub.3 and R.sub.4 may additionally be C.sub.1-4 alkylcarbonyl;

R.sub.5 is hydrogen or C.sub.1-10 alkyl;

R.sub.6 is hydrogen or R.sub.6 and R.sub.7 taken together are --(CH.sub.2).sub.3 --;

R.sub.7 is hydrogen; C.sub.1-7 alkyl; hydroxymethyl; mercaptomethyl; benzyl; or substituted benzyl;

R.sub.8 and R.sub.9 may be the same or different and are each independently COOR, or CONR'R", where R is hydrogen or C.sub.1-7 alkyl, and R' and R" are hydrogen or C.sub.1-3 alkyl;

when R.sub.5 is C.sub.1-10 alkyl, the stereochemistry at asymmetric center I is D or L;

when R.sub.7 is other than hydrogen, the stereochemistry at asymmetric center II is L; and the stereochemistry at asymmetric center III is D; and acid addition and quaternary salts thereof.

L12 ANSWER 13 OF 14 USPATFULL

AN 81:14980 USPATFULL

TI Immunologically active dipeptidyl saccharides and methods of preparation

IN Durette, Philippe L., New Providence, NJ, United States

Shen, Tsung-Ying, Westfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4256735 19810317

AI US 1979-7108 19790129 (6)

DT Utility

FS Granted

EXNAM Primary Examiner: Phillips, Delbert R.; Assistant Examiner: Hazel, Blondel

LREP Perrella, Donald J., Levitt, Julian S.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1,14

DRWN No Drawings

LN.CNT 1559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;

R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;

R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;

R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);

R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,

R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or substituted benzyl;

R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;

Provided that when R.sub.3 is lower alkyl, the stereochemistry at asymmetric center I can be either D or L, but that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, the stereochemistry at I cannot be D;

When R.sub.7 is not H, the stereochemistry at asymmetric center II is either L or D; and

The stereochemistry at asymmetric center III is D.

These compounds possess immunostimulatory properties.

L12 ANSWER 14 OF 14 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

AN 2000-128304 [12] WPIDS

DNC C2000-039402

TI New **vaccine** for prevention of **gram-negative** bacterial infections and endotoxin related disorders, comprises complex of **peptide** and **LPS**.

DC B04 B05 D16

IN PORRO, M

PA (BIOS-N) BIOSYNTH SRL

CYC 26

PI EP 976402 A2 20000202 (200012)\* EN 43p

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

CA 2279316 A1 20000129 (200028) EN

ADT EP 976402 A2 EP 1999-202476 19990727; CA 2279316 A1 CA 1999-2279316 19990729

PRAI US 1998-124280 19980729

AB EP 976402 A UPAB: 20000308

NOVELTY - A **vaccine** for preventing **gram negative** infections and the effects of endotoxins is new and comprises a complex obtained by combining **LPS** free or in conjugate form with a sufficient amount of a **peptide** which is capable of producing a non-toxic, highly immunogenic complex.

DETAILED DESCRIPTION - A **vaccine** for preventing **gram negative** infections and the effects of endotoxins is new and comprises a complex obtained by combining **LPS** free or in conjugate form with a sufficient amount of a **peptide** which is capable of producing a non-toxic, highly immunogenic complex. The **peptide** is of the formula (a) - (c):

(a) (A)<sub>n</sub>;

(b) (AB)<sub>m</sub>; and/or

(c) (ABC)<sub>p</sub>.

A = a cationic amino acid e.g. Lysine or Arginine;

B = a hydrophobic amino acid e.g. Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan;

C = a hydrophobic amino acid e.g. Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan;

n = integer of 7-16;

m = integer of 4-20;

p = integer of 4-20.

An INDEPENDENT CLAIM is also included for a method for the

preparation of a **vaccine** for prevention of **gram-negative** infections and the effects of endotoxins.

ACTIVITY - Antibacterial.

No relevant activity data given.

MECHANISM OF ACTION - The excess **peptide** significantly stabilizes the **LPS peptide** complex from the likely antagonistic activity of natural **LPS**-receptor proteins present on specialized cells of the immune system.

USE - The **vaccine** is useful for the prevention of bacterial infections caused by **gram-negative bacteria** and for the prevention of biological effects of homologous endotoxins, especially for preventing sepsis and septic shock.

ADVANTAGE - The toxic characteristic of **LPS** may be removed without eliminating the antigenic and immunogenic properties of **LPS** by binding the **LPS** (via the lipid A moiety) to a **peptide**.

Dwg.0/0

=> d his

(FILE 'HOME' ENTERED AT 12:03:48 ON 09 AUG 2001)

FILE 'EMBASE, MEDLINE, BIOSIS, USPATFULL, JAPIO, WPIDS, CAPLUS, AGRICOLA,

LIFESCI, BIOTECHDS, JICST-EPLUS' ENTERED AT 12:04:22 ON 09 AUG 2001

E PORRO MASSIMO/AU

E PORRO MASSIMO/AU

L1 40 S E3  
L2 20 S L1 AND BACTERIA  
L3 17 DUP REM L2 (3 DUPLICATES REMOVED)  
L4 17 S L1 AND GRAM NEGATIVE  
L5 8 S L4 AND LPS  
L6 14 S L1 AND LPS  
L7 12 DUP REM L6 (2 DUPLICATES REMOVED)  
L8 6792 S LPS AND PEPTID?  
L9 93 S L8 AND STOICHIOMETRIC  
L10 88 DUP REM L9 (5 DUPLICATES REMOVED)  
L11 65 S L10 AND (GRAM NEGATIVE OR BACTERIA)  
L12 14 S L11 AND VACCIN?

=> s l10 and (meningtidis or salmonella or moraxella or e coli or influenzae or pseudomonas)

6 FILES SEARCHED...

L13 70 L10 AND (MENINGTIDIS OR SALMONELLA OR MORAXELLA OR E COLI OR INFLUENZAE OR PSEUDOMONAS)

=> s l13 and vaccin?

L14 12 L13 AND VACCIN?

=> d l13 bib ab 1-40

L13 ANSWER 1 OF 70 USPATFULL

AN 2001:121486 USPATFULL

TI Substituted aryl hydroxamic acids as metalloproteinase inhibitors

IN Xue, Chu-Biao, Hockessin, DE, United States

Decicco, Carl P., Newark, DE, United States

Wexler, Ruth R., Wilmington, DE, United States

PA DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

PI US 6268379 B1 20010731

AI US 1999-311168 19990513 (9)  
PRAI US 1998-85393 19980514 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Davis, Zinna Northington  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1496  
AB The present application describes novel substituted aryl hydroxamic acids of formula I: ##STR1##

or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-2 heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.

L13 ANSWER 2 OF 70 USPATFULL  
AN 2001:116819 USPATFULL  
TI Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription  
IN Morgan, Antony R., late of Edmonton, Canada deceased  
Morgan, Robert Charles, Toronto, Canada executor  
Severini, Alberto, Edmonton, Canada  
PA DNAB Diagnostics, Inc., Edmonton, Canada (non-U.S. corporation)  
PI US 6265213 B1 20010724  
AI US 2000-593323 20000613 (9)  
RLI Division of Ser. No. US 1999-344300, filed on 24 Jun 1999  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Wilder, Cynthia  
LREP Medlen & Carroll, LLP  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 2418  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention provides plasmids that are useful in detecting and determining the DNA-binding activity of sequence-specific DNA-binding molecules. The invention further provides plasmids that are useful in detecting and determining the activity of RNA polymerases in initiating transcription. In particular, the invention relates to plasmids that contain unique restriction sites and cognate nucleotide recognition sequences for sequence-specific DNA-binding molecules. Also provided are methods for using the plasmids disclosed herein.

L13 ANSWER 3 OF 70 USPATFULL  
AN 2001:47850 USPATFULL  
TI Methods for early detection of heart disease  
IN Sabbadini, Roger A., Lakeside, CA, United States  
PA Medlyte Diagnostics, Inc., Lakeside, CA, United States (U.S. corporation)  
PI US 6210976 B1 20010403  
AI US 1998-84069 19980522 (9)  
PRAI US 1997-49274 19970610 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Chin, Christopher L.  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 1924  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to methods, compositions, kits, and devices for

detecting cardiac ischemia, hypoxia, or other causes of heart failure  
in a mammal by obtaining a test sample from a mammal, measuring a level of  
a non-polypeptidic cardiac marker in the test sample, and determining  
if the level of the cardiac marker measured in said test sample correlates  
with cardiac ischemia or hypoxia or another form of heart failure.

L13 ANSWER 4 OF 70 USPATFULL

AN 2001:33283 USPATFULL  
TI 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines  
IN DeNinno, Michael P., Gales Ferry, CT, United States  
Magnus-Aryitey, George T., Ledyard, CT, United States  
Ruggeri, Roger B., Waterford, CT, United States  
Wester, Ronald T., Ledyard, CT, United States  
PA Pfizer Inc, New York, NY, United States (U.S. corporation)  
PI US 6197786 B1 20010306  
AI US 1999-391152 19990907 (9)  
PRAI US 1998-100860 19980917 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Seaman, D. Margaret  
LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean  
CLMN Number of Claims: 45  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4999

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cholesteryl ester transfer protein inhibitors, pharmaceutical  
compositions containing such inhibitors and the use of such inhibitors  
to elevate certain plasma lipid levels, including high density  
lipoprotein-cholesterol and to lower certain other plasma lipid levels,  
such as LDL-cholesterol and triglycerides and accordingly to treat  
diseases which are exacerbated by low levels of HDL cholesterol and/or  
high levels of LDL-cholesterol and triglycerides, such as  
atherosclerosis and cardiovascular diseases in some mammals, including  
humans.

L13 ANSWER 5 OF 70 USPATFULL

AN 2001:1478 USPATFULL  
TI Use of antibodies to block the effects of gram-positive bacteria and  
mycobacteria  
IN Ulevitch, Richard J., Del Mar, CA, United States  
Tobias, Peter S., San Diego, CA, United States  
Pugin, Jerome, Puplinge, Switzerland  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S.  
corporation)  
PI US 6168790 B1 20010102  
AI US 1998-99957 19980619 (9)  
RLI Continuation of Ser. No. US 1994-307931, filed on 16 Sep 1994, now  
abandoned Continuation-in-part of Ser. No. US 1992-990378, filed on 15  
Dec 1992, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Smith, Lynette R. F.; Assistant Examiner: Portner,  
Ginny Allen  
LREP Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 1964

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns a method of treating bacteremia, sepsis  
and other forms of toxemia caused by Gram-positive bacteria and  
mycobacteria comprising administering a therapeutically effective  
amount

of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

L13 ANSWER 6 OF 70 USPATFULL

AN 2000:157145 USPATFULL

TI Nuclear factors associated with transcriptional regulation

IN Baltimore, David, New York, NY, United States

Sen, Ranjan, Cambridge, MA, United States

Sharp, Phillip A., Newton, MA, United States

Singh, Harinder, Chicago, IL, United States

Staudt, Louis, Silver Springs, MD, United States

LeBowitz, Jonathan H., Zionsville, IN, United States

Baldwin, Jr., Albert S., Chapel Hill, NC, United States

Clerc, Roger G., Binningen, Switzerland

Corcoran, Lynn M., Port Melbourne, Australia

Baeuerle, Patrick A., Eichenau, Germany, Federal Republic of

Lenardo, Michael J., Potomac, MD, United States

Fan, Chen-Ming, San Francisco, MA, United States

Maniatis, Thomas P., Belmont, MA, United States

PA Massachusetts Institute of Technology, Cambridge, MA, United States  
(U.S. corporation)

Whitehead Institute, Cambridge, MA, United States (U.S. corporation)

President and Fellows of Harvard College, Cambridge, MA, United States  
(U.S. corporation)

PI US 6150090 20001121

AI US 1995-463397 19950605 (8)

RLI Division of Ser. No. US 1995-418266, filed on 6 Apr 1995, now patented,  
Pat. No. US 5804374 which is a continuation of Ser. No. US 1991-791898,  
filed on 13 Nov 1991, now abandoned which is a continuation-in-part of  
Ser. No. US 1986-946365, filed on 24 Dec 1986, now abandoned And a  
continuation-in-part of Ser. No. US 1989-318901, filed on 3 Mar 1989,  
now abandoned And a continuation-in-part of Ser. No. US 1988-162680,  
filed on 1 Mar 1988, now abandoned And a continuation-in-part of Ser.  
No. US 1989-341436, filed on 21 Apr 1989, now abandoned And a  
continuation-in-part of Ser. No. US 1986-817441, filed on 9 Jan 1986,  
now abandoned And a continuation-in-part of Ser. No. US 1988-155207,  
filed on 12 Feb 1988, now abandoned And a continuation-in-part of Ser.  
No. US 1988-280173, filed on 5 Dec 1988, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartzman, Robert A.

LREP Foley, Hoag & Eliot, LLP, Vincent, Matthew P., Clauss, Isabelle M.

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 28 Drawing Figure(s); 24 Drawing Page(s)

LN.CNT 4899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Constitutive and tissue-specific protein factors which bind to  
transcriptional regulatory elements of Ig genes (promoter and enhancer)  
are described. The factors were identified and isolated by an improved  
assay for protein-DNA binding. Genes encoding factors which positively  
regulate transcription can be isolated and employed to enhance  
transcription of Ig genes. In particular, NF-kB, the gene encoding

NF-kB,

IkB and the gene encoding IkB and uses therefor.

L13 ANSWER 7 OF 70 USPATFULL

AN 2000:153723 USPATFULL

TI 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines

IN DeNinno, Michael P., Gales Ferry, CT, United States

Mularski, Christian J., Chester, CT, United States

Ruggeri, Roger B., Waterford, CT, United States

Wester, Ronald T., Ledyard, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)



PI US 6147090 20001114  
AI US 1999-391273 19990907 (9)  
PRAI US 1998-100929 19980917 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Seaman, D. Margaret  
LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean  
CLMN Number of Claims: 35  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3864  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 8 OF 70 USPATFULL

AN 2000:153722 USPATFULL  
TI Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines  
IN DeNinno, Michael P., Gales Ferry, CT, United States  
Ruggeri, Roger B., Waterford, CT, United States  
Wester, Ronald T., Ledyard, CT, United States  
PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 6147089 20001114  
AI US 1999-390738 19990907 (9)  
PRAI US 1998-100926 19980917 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Seaman, D. Margaret  
LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3412  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 9 OF 70 USPATFULL

AN 2000:146389 USPATFULL  
TI 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines  
IN DeNinno, Michael P., Gales Ferry, CT, United States  
Magnus-Aryitey, George T., Ledyard, CT, United States  
Ruggeri, Roger B., Waterford, CT, United States  
Wester, Ronald T., Ledyard, CT, United States  
PA Pfizer, New York, NY, United States (U.S. corporation)  
PI US 6140343 20001031  
AI US 1999-391313 19990907 (9)  
PRAI US 1998-100927 19980917 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Seaman, D. Margaret

LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean  
CLMN Number of Claims: 44  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4486

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 10 OF 70 USPATFULL

AN 2000:146388 USPATFULL  
TI Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines  
IN Goldstein, Steven W., Noank, CT, United States  
Makowski, Michael R., Salem, CT, United States  
Ruggeri, Roger B., Waterford, CT, United States  
Wester, Ronald T., Ledyard, CT, United States  
PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
PI US 6140342 20001031  
AI US 1999-390731 19990907 (9)  
PRAI US 1998-100729 19980917 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Seaman, D. Margaret  
LREP Richardson, Peter C., Benson, Gregg C., Olson, A. Dean  
CLMN Number of Claims: 44  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4488

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

L13 ANSWER 11 OF 70 USPATFULL

AN 2000:131642 USPATFULL  
TI Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having an endosome disruption agent  
IN Boutin, Raymond H., Thornton, PA, United States  
PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)  
PI US 6127170 20001003  
WO 9610038 19960404  
AI US 1997-809397 19970321 (8)  
WO 1995-US12502 19950928  
19970321 PCT 371 date  
19970321 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1994-314060, filed on 28 Sep 1994, now patented, Pat. No. US 5837533, issued on 17 Nov 1998  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Crouch, Deborah

LREP Howson and Howson  
CLMN Number of Claims: 49  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4293

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided. The complex is comprised of

A) said nucleic acid composition and B) a transfer moiety comprising 1) one or more cationic polyamines bound to said nucleic acid composition, 2) one or more endosome membrane disrupting components attached to at least one nitrogen of the polyamine and 3) one or more receptor specific binding components.

L13 ANSWER 12 OF 70 USPATFULL

AN 2000:125209 USPATFULL

TI Oligomeric compounds having nitrogen-containing linkages

IN Cook, Phillip Dan, Vista, CA, United States  
Sanghvi, Yogesh S., San Marcos, CA, United States  
Kung, Pei Pei, Carlsbad, CA, United States

PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)

PI US 6121433 20000919

WO 9518623 19950713

AI US 1996-669300 19960808 (8)

WO 1995-US350

19950111

19960808 PCT 371 date

19960808 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-180124, filed on 11 Jan 1994, now patented, Pat. No. US 5783682 And a continuation-in-part of Ser.

No.

US 1993-39979, filed on 30 Mar 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-39846, filed on 30 Mar 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-40933, filed on 31 Mar 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-40903, filed on 31 Mar 1993, now patented, Pat. No. US 5386023 And a continuation-in-part of Ser. No. US 1993-40526, filed on 31 Mar 1993, now patented, Pat. No. US 5489677 which is a continuation-in-part of Ser. No. WO 1992-US4294, filed on 21 May 1992 And a continuation-in-part of Ser. No. US 1992-903160, filed on 24 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-703619, filed on 21 May 1991, now patented, Pat. No. US 5378825 which is a continuation-in-part of Ser. No. US 1990-566836, filed on 13 Aug 1990, now patented, Pat. No. US 5223618 And a continuation-in-part of Ser. No. US 1990-558663, filed on 27 Jul 1990, now patented, Pat.

No.

US 5138045

DT Utility

FS Granted

EXNAM Primary Examiner: Marschel, Ardin H.; Assistant Examiner: Riley, Jezia

LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 3461

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds and libraries of compounds based on nitrogen atoms that are joined together with spanner groups include "letters" i.e., functional groups, that are attached to the nitrogen atoms, to the spanner groups or to both the nitrogen atoms and the spanner groups to render the compounds and libraries of such compounds with diverse properties.

L13 ANSWER 13 OF 70 USPATFULL  
 AN 2000:117742 USPATFULL  
 TI 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives  
 IN Robinson, Ralph P., Gales Ferry, CT, United States  
 Laird, Ellen R., Mystic, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6114361 20000905  
 AI US 1999-429937 19991029 (9)  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: McKane, Joseph; Assistant Examiner: Oswecki, Jane C.  
 LREP Richardson, Peter C., Ginsburg, Paul H., Jacobs, Seth  
 CLMN Number of Claims: 19  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 1761  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to a compound of the formula ##STR1##  
 wherein R.sup.1, R.sup.2, R.sup.3 are as defined above, to  
 pharmaceutical compositions and methods of treatment.

L13 ANSWER 14 OF 70 USPATFULL  
 AN 2000:113991 USPATFULL  
 TI Bicyclic hydroxamic acid derivatives  
 IN Robinson, Ralph Pelton, Gales Ferry, CT, United States  
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)  
 PI US 6110964 20000829  
 WO 9952910 19991021  
 AI US 1999-402259 19990930 (9)  
 WO 1999-IB503 19990324  
 19990930 PCT 371 date  
 19990930 PCT 102(e) date  
 PRAI US 1998-81309 19980410 (60)  
 US 1997-55208 19970808 (60)  
 US 1997-55207 19970808 (60)  
 US 1997-62766 19971024 (60)  
 US 1997-68261 19971219 (60)  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Lambkin, Deborah C.  
 LREP Richardson, Peter C., Ginsburg, Paul H., Appleman, Polene W.  
 CLMN Number of Claims: 27  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 1851  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A compound of the formula ##STR1## wherein Z and Q are as defined in  
 the  
 specification, to pharmaceutical compositions containing them and to  
 their medicinal use.

L13 ANSWER 15 OF 70 USPATFULL  
 AN 2000:106071 USPATFULL  
 TI Mammalian cationic proteins having lipopolysaccharide binding and  
 anti-coagulant activity  
 IN Larrick, James W., Woodside, CA, United States  
 Wright, Susan C., Saratoga, CA, United States  
 Hirata, Michimasa, Morioka, Japan  
 PA Panorama Research, Inc., Mountain View, CA, United States (U.S.  
 corporation)  
 PI US 6103888 20000815  
 AI US 1999-322911 19990601 (9)  
 RLI Continuation of Ser. No. US 1996-691280, filed on 1 Aug 1996 which is a  
 continuation-in-part of Ser. No. US 313681

DT Utility  
FS Granted  
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Portner, Ginny Allen  
LREP Townsend and Townsend and Crew  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 30 Drawing Figure(s); 20 Drawing Page(s)  
LN.CNT 1944

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian

granulocytes, particularly including a reactive nitrogen inhibiting peptide (RNIP) fragment found at the carboxy-terminus of CAP18.

Polypeptides are capable of binding to LPS and inhibiting LPS-mediated activation of macrophage, as well as interfering with the clotting cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in a suitable pharmaceutical carrier are also provided.

L13 ANSWER 16 OF 70 USPATFULL

AN 2000:84288 USPATFULL

TI Substituted imidazoles having anti-cancer and cytokine inhibitory activity

IN Liverton, Nigel J., Harleysville, PA, United States  
Claiborne, Christopher F., Lansdale, PA, United States  
Claremon, David A., Maple Glen, PA, United States  
Selnick, Harold G., Ambler, PA, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 6083949 20000704

AI US 1998-13527 19980126 (9)

RLI Continuation-in-part of Ser. No. US 1996-717955, filed on 23 Sep 1996, now patented, Pat. No. US 5717100

DT Utility

FS Granted

EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita

LREP Korsen, Elliott, Daniel, Mark R.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds represented by formula I: ##STR1## are disclosed. AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom.

A pharmaceutical composition is also included.

Methods of treating cancer and cytokine mediated diseases are also included.

L13 ANSWER 17 OF 70 USPATFULL

AN 2000:61580 USPATFULL

TI Method for using lipoprotein associated coagulation inhibitor to treat sepsis

IN Creasey, Abba A., Piedmont, CA, United States  
Broze, George J., Ladue, MO, United States

PA Washington University & Chiron Corp., United States (U.S. corporation)

PI US 6063764 20000516

AI US 1995-472761 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-224118, filed on 29 Mar 1994, now abandoned which is a continuation of Ser. No. US 1993-20427, filed on 22 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-897135, filed on 11 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1994-253427, filed on 2 Jun 1994, now abandoned which is a continuation of Ser. No. US 1993-4505, filed

on

13 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-891947, filed on 1 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1994-270455, filed on 5 Jul 1994, now abandoned which is a continuation of Ser. No. US 1992-891947, filed on 1 Jun 1992, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Tsang, Cecilia; Assistant Examiner: Delacroix-Muirheid, C.

LREP Banner & Witcoff, Ltd.

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 2568

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to pateints. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.

L13 ANSWER 18 OF 70 USPATFULL

AN 2000:41164 USPATFULL

TI Antisense oligodeoxynucleotides regulating expression of TNF-.alpha.

IN Power, Christopher, Calgary, Canada

Mayne, Michael B., Winnipeg, Canada

PA University Technologies International, Inc., Canada (non-U.S. corporation)

PI US 6046319 20000404

AI US 1998-176862 19981022 (9)

PRAI US 1997-62718 19971022 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Epps, Janet

L.

LREP Kohn & Associates

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1447

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A synthetic nuclease resistant antisense oligodeoxynucleotide capable of

selectively modulating expression of human tumor necrosis factor-alpha by targeting exon sequences flanking donor splice sites, thereby regulating expression of TNF-.alpha. in a patient in need of such therapy is provided. In an embodiment either AS-ODN having the sequence set forth in SEQ ID No:4 or SEQ ID No:6 or a combination thereof can be used. The AS-ODN is administered either as the active ingredient in a pharmaceutical composition or by utilizing gene therapy techniques as

an

expression vector.

L13 ANSWER 19 OF 70 USPATFULL

AN 2000:40640 USPATFULL

TI Methods and compositions for ameliorating the symptoms of sepsis  
IN Ulevitch, Richard, Del Mar, CA, United States  
Tobias, Peter, Encinitas, CA, United States  
Wright, Samuel D., New York, NY, United States  
Mathison, John C., San Diego, CA, United States  
PA The Scripps Research Institute, La Jolla, CA, United States (U.S.  
corporation)  
PI US 6045795 20000404  
AI US 1997-906400 19970805 (8)  
RLI Continuation of Ser. No. US 1994-328554, filed on 25 Oct 1994, now  
patented, Pat. No. US 5730980 which is a continuation of Ser. No. US  
1992-990378, filed on 15 Dec 1992, now abandoned which is a

continuation  
of Ser. No. US 1989-387817, filed on 1 Aug 1989, now abandoned

DT Utility  
FS Granted  
EXNAM Primary Examiner: Budens, Robert D.  
LREP Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 1379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns a method of treating sepsis comprising  
administering a therapeutically effective amount of anti-CD14 antibody  
molecules. A therapeutic composition comprising anti-CD14 antibody  
molecules in a pharmaceutically acceptable excipient is also  
contemplated.

L13 ANSWER 20 OF 70 USPATFULL

AN 2000:4818 USPATFULL

TI 2-(arylalkenyl) azacycloalkane derivatives as ligands for sigma  
receptors

IN Calvet, Alain Pierre, L'Hay-les-Roses, France  
Jacobelli, Henry, Paray-Vieille-Poste, France  
Junien, Jean-Louis, Sevres, France  
Riviere, Pierre, Paris, France  
Roman, Fran.cedilla.ois-Joseph, Vitry-sur-Seine, France  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S.  
corporation)

PI US 6013656 20000111

AI US 1998-145918 19980902 (9)

RLI Division of Ser. No. US 1996-652567, filed on 7 Jun 1996, now patented,  
Pat. No. US 5849760 which is a continuation of Ser. No. WO 1994-FR1439,  
filed on 9 Dec 1994

PRAI FR 1993-14814 19931209

DT Utility

FS Granted

EXNAM Primary Examiner: Raymond, Richard L.

LREP Ashbrook, Charles W.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1507

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New 2-(arylalkenyl)azacycloalkane derivatives which are ligands for  
sigma receptors, of the formula (I) ##STR1## in which: Ar is aryl or  
heteroaryl, optionally mono- to trisubstituted,

m has the value 1 or 2,

n has the value 1 to 3,

R is phenyl, or cycloalkyl containing 3 to 7 carbon atoms,

their isomers and their addition salts.

Medicinal drugs which are antipsychotic agents and are useful in gastroenterology.

L13 ANSWER 21 OF 70 USPATFULL

AN 1999:132526 USPATFULL

TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting

IN Goldberg, Alfred L., Brookline, MA, United States

PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

PI US 5972636 19991026

AI US 1997-982295 19971202 (8)

RLI Division of Ser. No. US 1996-730310, filed on 11 Oct 1996, now patented,

Pat. No. US 5786329 which is a division of Ser. No. US 1994-262497, filed on 20 Jun 1994, now patented, Pat. No. US 5565351 which is a division of Ser. No. US 1991-699184, filed on 13 May 1991, now

patented,

Pat. No. US 5340736

DT Utility

FS Granted

EXNAM Primary Examiner: Patterson, Jr., Charles L.

LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 12 Drawing Page(s)

LN.CNT 2944

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The ATP-ubiquitin-dependent process has been shown to be responsible for

the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L13 ANSWER 22 OF 70 USPATFULL

AN 1999:113766 USPATFULL

TI Triaryl substituted imidazoles, compositions containing such compounds and methods of use

IN Chang, Linda L., Wayne, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5955480 19990921

AI US 1997-972021 19971117 (8)

PRAI US 1996-31467 19961120 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Fan, Jane

LREP Yang, Mollie M., Rose, David L.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1845

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 2,4-Diaryl-5-pyridylimidazoles are glucagon antagonists and inhibitors of the biosynthesis and/or action of TNF-.alpha. and IL-1. The compounds

block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose. The instant imidazoles are also inhibitors of TNF-.alpha. and IL-1. Compounds of the present invention may be used

for



glucagon-mediated as well as cytokine mediated diseases. Cytokine mediated diseases refers to diseases or conditions in which excessive

or

unregulated production of one or more cytokines occurs. Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are cytokines produced by a variety of cells, which are involved in immunoregulation and other physiological conditions, such as inflammation.

L13 ANSWER 23 OF 70 USPATFULL

AN 1999:113664 USPATFULL

TI Methods and kits for the amplification of thin film based assays

IN Maul, Diana M., Thornton, CO, United States

Bogart, Gregory R., Fort Collins, CO, United States

PA Biostar, Inc., Boulder, CO, United States (U.S. corporation)

PI US 5955377 19990921

AI US 1995-403565 19950417 (8)

RLI Continuation of Ser. No. US 1993-75693, filed on 10 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-923090, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-653052, filed on 11 Feb 1991

PRAI EP 1991-308968 19911001

DT Utility

FS Granted

EXNAM Primary Examiner: Chin, Christopher L.

LREP Lyon & Lyon LLP

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 62 Drawing Figure(s); 23 Drawing Page(s)

LN.CNT 5421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for detecting an analyte of interest, comprising the steps of providing a detection device comprising a light reflective or transmissive substrate supporting one or more layers comprising an adhering attachment layer to which is affixed a receptive material

which

specifically interacts with the analyte of interest; reacting the

device

with a sample potentially comprising the analyte under conditions in which the analyte binds to the receptive material; and reacting bound analyte with a reagent which creates a mass change on the surface of

the

device.

L13 ANSWER 24 OF 70 USPATFULL

AN 1999:89171 USPATFULL

TI Matrix metalloprotease inhibitors

IN Bender, Steven Lee, Oceanside, CA, United States

Broka, Chris Allen, Foster City, CA, United States

Campbell, Jeffrey Allen, Fremont, CA, United States

Castelhamo, Arlindo Lucas, New York, NY, United States

Fisher, Lawrence Emerson, Mountain View, CA, United States

Hendricks, Robert Than, Palo Alto, CA, United States

Sarma, Keshab, Sunnyvale, CA, United States

PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)

Agouron Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)

PI US 5932595 19990803

AI US 1996-769049 19961218 (8)

PRAI US 1996-22439 19960807 (60)

US 1995-8939 19951220 (60)

US 1996-32096 19961204 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Kight, John; Assistant Examiner: Covington, Raymond

LREP Peries, Rohan

CLMN Number of Claims: 60  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4966

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of Formula I: ##STR1## that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.

L13 ANSWER 25 OF 70 USPATFULL

AN 1999:89112 USPATFULL

TI Compositions for neutralization of lipopolysaccharides

IN Wright, Samuel D., Larchmont, NY, United States

Wurfel, Mark M., New York, NY, United States

Hailman, Peter Eric, New York, NY, United States

PA The Rockefeller University, New York, NY, United States (U.S. corporation)

PI US 5932536 19990803

AI US 1994-337611 19941110 (8)

RLI Continuation-in-part of Ser. No. US 1994-259957, filed on 14 Jun 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Mohamed, Abdel A.

LREP Klauber & Jackson

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 22 Drawing Page(s)

LN.CNT 2132

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods for neutralizing lipopolysaccharide, and treatment of gram-negative sepsis based therein. Accordingly, the invention is directed to a composition of homogeneous particles comprising phospholipids and a lipid exchange protein, such as phospholipid transfer protein or LPS binding protein. The lipid exchange protein is characterized by being capable

of

facilitating an exchange protein of lipopolysaccharide into the particles. In a specific embodiment, exemplified herein, the lipid particles are high density lipoprotein particles comprising apolipoprotein A-I (apo A-I), a phospholipid, and cholesterol or a

lipid

bilayer binding derivative thereof. In a specific example, the phospholipid is phosphatidylcholine (PC). In a specific example, the ratio of phosphatidylcholine:cholesterol:apolipoprotein A-I is approximately 80:4:1. The levels of LPS exchange protein activity in a sample from a patient provides a diagnostic, monitoring, or prognostic indicator for a subject with endotoxemia, gram-negative sepsis, or septic shock.

L13 ANSWER 26 OF 70 USPATFULL

AN 1999:84975 USPATFULL

TI Compositions for neutralization of lipopolysaccharides

IN Wright, Samuel D., Westfield, NJ, United States

Wurfel, Mark M., New York, NY, United States

Hailman, Peter Eric, New York, NY, United States

PA The Rockefeller University, New York, NY, United States (U.S. corporation)

PI US 5928624 19990727

WO 9534289 19951221

AI US 1996-750697 19961216 (8)

WO 1995-US7903 19950607

19961216 PCT 371 date

RLI Continuation-in-part of Ser. No. US 1994-337611, filed on 10 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-259957, filed on 14 Jun 1994, now abandoned  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Kishore, Gollamudi S.  
 LREP Klauber & Jackson  
 CLMN Number of Claims: 12  
 ECL Exemplary Claim: 1  
 DRWN 33 Drawing Figure(s); 32 Drawing Page(s)  
 LN.CNT 2562

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods for neutralizing lipopolysaccharide, and treatment of gram-negative sepsis based thereon. Accordingly, the invention is directed to a composition of homogeneous particles comprising phospholipids and a lipid exchange protein, such as phospholipid transfer protein or **LPS** binding protein. The lipid exchange protein is characterized by being capable of facilitating an exchange of lipopolysaccharide into the particles. In a specific embodiment, exemplified herein, the lipid particles are high density lipoprotein particles comprising apolipoprotein A-I (apo A-I), a phospholipid, and cholesterol or a lipid bilayer binding derivative thereof. In a specific example, the phospholipid is phosphatidylcholine (PC). In a specific example, the ratio of phosphatidylcholine: cholesterol: apolipoprotein A-I is approximately 80:4:1. The level of **LPS** exchange protein activity in a sample from a patient provides a diagnostic, monitoring, or prognostic indicator for a subject with endotoxemia, gram-negative sepsis, or septic shock.

L13 ANSWER 27 OF 70 USPATFULL

AN 1999:18941 USPATFULL  
 TI Methods for detection of gram negative bacteria  
 IN Bogart, Gregory R., Berthoud, CO, United States  
 Moddel, Garret R., Boulder, CO, United States  
 Maul, Diana M., Thornton, CO, United States  
 Etter, Jeffrey B., Boulder, CO, United States  
 Crosby, Mark, Niwot, CO, United States  
 PA Biostar, Inc., Boulder, CO, United States (U.S. corporation)  
 PI US 5869272 19990209  
 AI US 1995-455652 19950531 (8)  
 RLI Division of Ser. No. US 1993-75952, filed on 10 Jun 1993, now patented, Pat. No. US 5541057 which is a continuation-in-part of Ser. No. US 1992-924343, filed on 31 Jul 1992, now abandoned Ser. No. US 1992-873097, filed on 24 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408291, filed on 18 Sep 1989, now abandoned  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Chin, Christopher L.  
 LREP Lyon & Lyon LLP  
 CLMN Number of Claims: 18  
 ECL Exemplary Claim: 1  
 DRWN 62 Drawing Figure(s); 23 Drawing Page(s)  
 LN.CNT 5224

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for the determination of chlamydial or gram negative bacterial antigen comprising contacting a sample potentially containing extracted antigen with an optically active surface comprising an attachment layer, and a layer of non-specific protein.

L13 ANSWER 28 OF 70 USPATFULL

AN 1998:157362 USPATFULL

TI 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors

IN Calvet, Alain Pierre, L'Hay-les-Roses, France

Jacobelli, Henry, Paray-Vieille-Poste, France

Junien, Jean-Louis, Sevres, France

Riviere, Pierre, Paris, France

Roman, Fran.cedilla.ois-Joseph, Vitry-sur-Seine, France

PA Institut de Recherche Jouveinal, Fresnes, France (non-U.S. corporation)

PI US 5849760 19981215

WO 9515948 19950615

AI US 1996-652567 19960607 (8)

WO 1993-FR9401439 19931209

19960110 PCT 371 date

19960110 PCT 102(e) date

PRAI FR 1993-14814 19931209

DT Utility

FS Granted

EXNAM Primary Examiner: Raymond, Richard L.

LREP Crissey, Todd M.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 1549

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New 2-(arylalkenyl)azacycloalkane derivatives which are ligands for sigma receptors, of the formula (I) ##STR1## in which: Ar is aryl or heteroaryl, optionally mono- to trisubstituted,

m has the value 1 or 2,

n has the value 1 to 3,

R is phenyl, or cycloalkyl containing 3 to 7 carbon atoms,

their isomers and their addition salts. Medicinal drugs which are antipsychotic agents and are useful in gastroenterology.

L13 ANSWER 29 OF 70 USPATFULL

AN 1998:143936 USPATFULL

TI Complexes comprising a nucleic acid bound to a cationic polyamine having

an endosome disruption agent

IN Boutin, Raymond H., Thornton, PA, United States

PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)

PI US 5837533 19981117

AI US 1994-314060 19940928 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Crouch, Deborah

LREP Howson and Howson

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3984

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided which comprises in any functional combination: A) said nucleic acid composition; and B) a transfer moiety comprising 1) one or more cationic polyamine components bound to said nucleic acid composition, each comprising from three to twelve nitrogen atoms; 2) one or more endosome membrane disruption promoting components attached to at least one nitrogen atom of at least

one of said polyamine components, through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group, comprising a) at least one lipophilic long chain alkyl group, b) a fusogenic peptide comprising spike glycoproteins of enveloped animal viruses, or c) cholic acid or cholesteryl or derivatives; and optionally

3) one or more receptor specific binding components which are ligands for natural receptors of said target cell, attached through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group to either i) a further nitrogen atom of at least one of said polyamine components to which said one or more endosome membrane disruption promoting components is attached, or ii) a nitrogen atom of at least one

further polyamine component which does not have attached thereto any endosome membrane disruption promoting component. Also provided are the transfer moiety alone, or in combination with the nucleic acid composition as a self-assembling combination, and the use of these compositions in methods for transferring nucleic acid compositions to cells or to cells of individuals, for immunizing individuals against a pathogen or disease, and for treating an individual with a disease.

L13 ANSWER 30 OF 70 USPTAFULL

AN 1998:108431 USPTAFULL

TI Aromatic hydroxamic acid compounds, their production and use

IN Kato, Kaneyoshi, Kawanishi, Japan

Miki, Shokyo, Ibaraki, Japan

Naruo, Ken-ichi, Sanda, Japan

Takahashi, Hideki, Ikeda, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

PI US 5804601 19980908

AI US 1996-629623 19960409 (8)

PRAI JP 1995-84342 19950410

JP 1995-215932 19950824

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Fitzpatrick, Cella, Harper & Scinto

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4448

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a compound of the formula: ##STR1## wherein Ar represents an optionally substituted aromatic group; Q represents a divalent aliphatic hydrocarbon group; R.sub.1 represents hydrogen, cyano, an optionally substituted hydrocarbon group, a group

of the formula: ##STR2## wherein R.sup.3 and R.sub.4 independently represent hydrogen, acyl or an optionally substituted hydrocarbon

group, or R.sup.3 and R.sup.4 jointly form a ring, or acyl; R.sup.2 represents acyl; ..... represents a single bond or a double bond; m represents 1 or 2 or a salt, a process of producing thereof and an anti-neurodegenerative composition.

L13 ANSWER 31 OF 70 USPTAFULL

AN 1998:108212 USPTAFULL

TI Nuclear factors associates with transcriptional regulation

IN Baltimore, David, New York, NY, United States

Sen, Ranjan, Cambridge, MA, United States

Sharp, Phillip A., Newton, MA, United States

Singh, Harinder, Chicago, IL, United States

Staudt, Louis, Silver Springs, MD, United States

LeBowitz, Jonathan H., Zionsville, IN, United States

Baldwin, Jr., Albert S., Chapel Hill, NC, United States

Clerc, Roger G., Binningen, Switzerland  
 Corcoran, Lynn M., Victoria, Australia  
 Baeuerle, Patrick A., Eichenau, Germany, Federal Republic of  
 Lenardo, Michael J., Potomac, MD, United States  
 Fan, Chen-Ming, San Francisco, MA, United States  
 Maniatis, Thomas P., Belmont, MA, United States  
 PA Massachusetts Insti. Technology, Cambridge, MA, United States (U.S. corporation)  
 Whitehead Insti., Cambridge, MA, United States (U.S. corporation)  
 Pres. and Fellow of Harvard College, Cambridge, MA, United States (U.S. corporation)  
 PI US 5804374 19980908  
 AI US 1995-418266 19950406 (8)  
 RLI Continuation of Ser. No. US 1991-791898, filed on 13 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1986-946365, filed on 24 Dec 1986, now abandoned And Ser. No. US 1989-318901, filed on 3 Mar 1989, now abandoned And Ser. No. US 1988-162680, filed on 1 Mar 1988, now abandoned And Ser. No. US 1989-341436, filed on 21 Apr 1989, now abandoned And Ser. No. US 1986-817441, filed on 9 Jan 1986, now abandoned And Ser. No. US 1988-155207, filed on 12 Feb 1988, now abandoned And Ser. No. US 1980-280173, filed on 5 Dec 1980, now abandoned  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Degen, Nancy  
 LREP Hamilton, Brook, Smith & Reynolds, P.C.  
 CLMN Number of Claims: 5  
 ECL Exemplary Claim: 1  
 DRWN 25 Drawing Figure(s); 24 Drawing Page(s)  
 LN.CNT 4692  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB,  
 IkB and the gene encoding IkB and uses therefor.  
 L13 ANSWER 32 OF 70 USPATFULL  
 AN 1998:108028 USPATFULL  
 TI Treatment of lipopolysaccharide- or CD14-mediated conditions using soluble CD14  
 IN Goyert, Sanna M., 10 Waterside Plz., Apt. 36F, New York, NY, United States 10010  
 PA Goyert, Sanna M., New York, NY, United States (U.S. individual)  
 PI US 5804189 19980908  
 AI US 1994-254095 19940606 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-863913, filed on 6 Apr 1992, now abandoned  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Spector, Lorraine M.  
 LREP Cooper, Iver P.  
 CLMN Number of Claims: 12  
 ECL Exemplary Claim: 1  
 DRWN 14 Drawing Figure(s); 7 Drawing Page(s)  
 LN.CNT 1204  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Methods are provided for the treatment of symptoms of sepsis and other conditions that are mediated by the action of CD14 myelomonocytic antigen ("CD14"). The embodiments herein include treatments for symptoms

of sepsis that are triggered by lipopolysaccharide ("LPS"). A genetically engineered recombinant soluble CD14 ("rsCD14") and fragments thereof are also provided. Both rsCD14 and a fragment thereof have been isolated and purified. The rsCD14 or fragments thereof can be administered to mammals to prevent or treat symptoms that are associated with sepsis.

L13 ANSWER 33 OF 70 USPATFULL

AN 1998:88814 USPATFULL

TI ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting

IN Goldberg, Alfred L., Brookline, MA, United States

PA The President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

PI US 5786329 19980728

AI US 1996-730310 19961011 (8)

RLI Division of Ser. No. US 1994-262497, filed on 20 Jun 1994, now patented,

Pat. No. US 5565351 which is a division of Ser. No. US 1991-699184, filed on 13 May 1991, now patented, Pat. No. US 5340736

DT Utility

FS Granted

EXNAM Primary Examiner: Patterson, Jr., Charles L.

LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2887

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The ATP-ubiquitin-dependent process has been shown to be responsible for

the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

L13 ANSWER 34 OF 70 USPATFULL

AN 1998:51440 USPATFULL

TI Method of rapid analyte detection

IN Olstein, Alan D., Mendota Heights, MN, United States

Albert, Richard, Eden Prairie, MN, United States

PA MicroQuest Diagnostics, Inc., Eden Prairie, MN, United States (U.S. corporation)

PI US 5750357 19980512

AI US 1995-380643 19950130 (8)

RLI Continuation-in-part of Ser. No. US 1994-245374, filed on 18 May 1994, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Scheiner, Toni R.

LREP Muetting, Raasch & Gebhardt, P.A.

CLMN Number of Claims: 32

ECL Exemplary Claim: 11,14

DRWN No Drawings

LN.CNT 872

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A detectable synthetic copolymer useful to detect the presence of a microorganism in a test sample is provided. The copolymer comprises repeating monomeric units, which incorporate a population of first monomeric units each comprising a binding agent which binds to a

microorganism having multiple binding sites for said binding agent and which further incorporates a population of a second monomeric units  
each comprising a detectable label or a binding site for a detectable label.

L13 ANSWER 35 OF 70 USPATFULL

AN 1998:39493 USPATFULL

TI Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

IN Roy, Soumitra, San Francisco, CA, United States

Vehar, Gordon A., San Carlos, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5739101 19980414

AI US 1995-440814 19950515 (8)

RLI Division of Ser. No. US 1994-246978, filed on 20 May 1994, now patented,

Pat. No. US 5589363 which is a division of Ser. No. US 1991-714819, filed on 13 Jun 1991, now patented, Pat. No. US 5346991

DT Utility

FS Granted

EXNAM Primary Examiner: Jacobson, Dian C.

LREP Kubinec, Jeffrey S.

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 7 Drawing Page(s)

LN.CNT 2482

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is

useful

in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.

L13 ANSWER 36 OF 70 USPATFULL

AN 1998:30695 USPATFULL

TI Methods and compositions for ameliorating the symptoms of sepsis

IN Ulevitch, Richard, Del Mar, CA, United States

Tobias, Peter, Encinitas, CA, United States

Wright, Samuel D., New York, NY, United States

Mathison, John C., San Diego, CA, United States

PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

PI US 5730980 19980324

AI US 1994-328554 19941025 (8)

RLI Continuation of Ser. No. US 1992-990378, filed on 15 Dec 1992, now abandoned which is a continuation of Ser. No. US 1989-387817, filed on

1

Aug 1989, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Sidberry, Hazel F.

LREP Fish & Richardson P.C.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 1316

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns a method of treating CD14-mediated host inflammatory response to LPS often associated with sepsis comprising administering a therapeutically effective amount of

anti-CD14

antibody molecules. A therapeutic composition comprising anti-CD14



antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

L13 ANSWER 37 OF 70 USPATFULL

AN 1998:14942 USPATFULL

TI Substituted imidazoles having anti-cancer and cytokine inhibitory activity

IN Selnick, Harold G., Ambler, PA, United States

Claremon, David A., Maple Glen, PA, United States

Liverton, Nigel J., Harleysville, PA, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 5717100 19980210

AI US 1996-717955 19960923 (8)

PRAI US 1995-5063 19951006 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Aulakh, Charanjit S.

LREP Billups, Richard C., Daniel, Mark R.

CLMN Number of Claims: 33

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3169

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds represented by formula I: ##STR1## are disclosed. AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 6 membered non-aromatic heterocycle containing only one N atom.

A pharmaceutical composition is also included.

Methods of treating cancer and cytokine mediated diseases are also included.

L13 ANSWER 38 OF 70 USPATFULL

AN 97:120632 USPATFULL

TI Methods of increasing thrombomodulin expression

IN Calnek, David S., Indianapolis, IN, United States

Grinnell, Brian W., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5700815 19971223

AI US 1995-517517 19950821 (8)

RLI Continuation of Ser. No. US 1993-170944, filed on 21 Dec 1993, now patented, Pat. No. US 5476862

DT Utility

FS Granted

EXNAM Primary Examiner: Fay, Zohreh

LREP Sales, James J.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 579

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of increasing thrombomodulin expression comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl;

R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

wherein

R.sup.1 and R.sup.3 are independently hydrogen, ##STR3## wherein Ar is optionally substituted phenyl;

R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof.

Also encompassed by the invention is a method of inhibiting a thrombotic disorder or event which includes administering to a human in need thereof an effective amount of a compound of formula 1.

Also encompassed by the invention is a method of increasing Protein C activation rate which includes the administration of a compound of formula 1.

L13 ANSWER 39 OF 70 USPATFULL

AN 97:51921 USPATFULL

TI Methods for optimizing of an optical assay device

IN Bogart, Gregory R., Fort Collins, CO, United States

Etter, Jeffrey B., Boulder, CO, United States

PA Biostar, Inc., Boulder, CO, United States (U.S. corporation)

PI US 5639671 19970617

AI US 1995-412600 19950328 (8)

RLI Continuation of Ser. No. US 1993-76319, filed on 10 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-923048, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-873097, filed on 24 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408291, filed on 18 Sep 1989, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Chin, Christopher L.

LREP Lyon & Lyon

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 62 Drawing Figure(s); 23 Drawing Page(s)

LN.CNT 5193

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for optimizing an optical assay device for an analyte, including the steps of: providing a substrate having a chosen thickness of an optically active layer thereon; providing an attachment layer of a chosen thickness on the optical coating; providing a receptive layer of a chosen thickness for the analyte, wherein at least one of the thicknesses of the optically active layer, attachment layer and receptive layer is varied to provide a plurality of thicknesses of that layer; contacting analyte with the receptive layer under conditions in which an increase in mass on the receptive layer results; and determining the optical thickness of the layer.

L13 ANSWER 40 OF 70 USPATFULL

AN 97:42799 USPATFULL

TI Method and instrument for detection of change of thickness or refractive

index for a thin film substrate

IN Sandstrom, Torbjorn, Molnlycke, Sweden

Stibler, Lars, G oteborg, Sweden

Maul, Diana M., Thornton, CO, United States

PA Biostar, Inc., Boulder, CO, United States (U.S. corporation)

PI US 5631171 19970520

AI US 1995-455493 19950531 (8)

RLI Continuation of Ser. No. US 1993-75128, filed on 10 Jun 1993, now patented, Pat. No. US 5494829 which is a continuation-in-part of Ser. No. US 1992-923268, filed on 31 Jul 1992, now abandoned

DT Utility  
FS Granted  
EXNAM Primary Examiner: Chin, Christopher L.  
LREP Lyon & Lyon  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 62 Drawing Figure(s); 23 Drawing Page(s)  
LN.CNT 5160  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB An instrument configured and arranged to detect a change in thickness  
or  
refractive index of a thin film substrate. A method for optimizing the  
instrument and a method for detecting a change in thickness or  
refractive index of a thin film substrate.

=> d bib ab 1-80

L14 ANSWER 1 OF 12 USPATFULL  
AN 2001:116819 USPATFULL  
TI Compositions and methods for determining the activity of DNA-binding  
proteins and of initiation of transcription  
IN Morgan, Antony R., late of Edmonton, Canada deceased  
Morgan, Robert Charles, Toronto, Canada executor  
Severini, Alberto, Edmonton, Canada  
PA DNAB Diagnostics, Inc., Edmonton, Canada (non-U.S. corporation)  
PI US 6265213 B1 20010724  
AI US 2000-593323 20000613 (9)  
RLI Division of Ser. No. US 1999-344300, filed on 24 Jun 1999  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Wilder,  
Cynthia  
LREP Medlen & Carroll, LLP  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 2418  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention provides plasmids that are useful in detecting and  
determining the DNA-binding activity of sequence-specific DNA-binding  
molecules. The invention further provides plasmids that are useful in  
detecting and determining the activity of RNA polymerases in initiating  
transcription. In particular, the invention relates to plasmids that  
contain unique restriction sites and cognate nucleotide recognition  
sequences for sequence-specific DNA-binding molecules. Also provided  
are  
methods for using the plasmids disclosed herein.

L14 ANSWER 2 OF 12 USPATFULL  
AN 2000:131642 USPATFULL  
TI Multifunctional complexes for gene transfer into cells comprising a  
nucleic acid bound to a polyamine and having a endosome disruption  
agent  
IN Boutin, Raymond H., Thornton, PA, United States  
PA American Home Products Corporation, Madison, NJ, United States (U.S.  
corporation)  
PI US 6127170 20001003  
WO 9610038 19960404  
AI US 1997-809397 19970321 (8)  
WO 1995-US12502 19950928  
19970321 PCT 371 date  
19970321 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1994-314060, filed on 28 Sep 1994,

now patented, Pat. No. US 5837533, issued on 17 Nov 1998  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Crouch, Deborah  
LREP Howson and Howson  
CLMN Number of Claims: 49  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4293

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided. The complex is comprised of

A) said nucleic acid composition and B) a transfer moiety comprising 1) one or more cationic polyamines bound to said nucleic acid composition, 2) one or more endosome membrane disrupting components attached to at least one nitrogen of the polyamine and 3) one or more receptor specific binding components.

L14 ANSWER 3 OF 12 USPATFULL

AN 1998:143936 USPATFULL

TI Complexes comprising a nucleic acid bound to a cationic polyamine having

an endosome disruption agent

IN Boutin, Raymond H., Thornton, PA, United States

PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)

PI US 5837533 19981117

AI US 1994-314060 19940928 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Crouch, Deborah

LREP Howson and Howson

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3984

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multifunctional molecular complex for the transfer of a nucleic acid composition to a target cell is provided which comprises in any functional combination: A) said nucleic acid composition; and B) a transfer moiety comprising 1) one or more cationic polyamine components bound to said nucleic acid composition, each comprising from three to twelve nitrogen atoms; 2) one or more endosome membrane disruption promoting components attached to at least one nitrogen atom of at least one of said polyamine components, through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group, comprising a) at least one lipophilic long chain alkyl group, b) a fusogenic peptide comprising spike glycoproteins of enveloped animal viruses, or c) cholic acid or cholesteryl or derivatives; and

optionally

3) one or more receptor specific binding components which are ligands for natural receptors of said target cell, attached through an alkyl, carboxamide, carbamate, thiocarbamate, or carbamoyl bridging group to either i) a further nitrogen atom of at least one of said polyamine components to which said one or more endosome membrane disruption promoting components is attached, or ii) a nitrogen atom of at least

one

further polyamine component which does not have attached thereto any endosome membrane disruption promoting component. Also provided are the transfer moiety alone, or in combination with the nucleic acid composition as a self-assembling combination, and the use of these compositions in methods for transferring nucleic acid compositions to

cells or to cells of individuals, for immunizing individuals against a pathogen or disease, and for treating an individual with a disease.

L14 ANSWER 4 OF 12 USPATFULL

AN 96:120869 USPATFULL

TI Synthetic **peptides** for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA Biosynth s.r.l., Siena, Italy (non-U.S. corporation)

PI US 5589459 19961231

AI US 1994-280397 19940726 (8)

RLI Division of Ser. No. US 1992-819893, filed on 16 Jan 1992, now patented,

Pat. No. US 5371186 which is a continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Davenport, Avis M.

LREP Hedman, Gibson & Costigan, P.C.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of using **peptides** of the formula R.sub.1 --(A--B--C).sub.n --R, wherein R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys and

Arg;

B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The **peptides** are used for the removal of endotoxin from blood or sera; the detoxification of bacterial endotoxin; and the prevention of the contamination of

products

with endotoxin.

L14 ANSWER 5 OF 12 USPATFULL

AN 94:106884 USPATFULL

TI Synthetic **peptides** for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock

IN Porro, Massimo, Siena, Italy

PA Biosynth S.r.l., Siena, Italy (non-U.S. corporation)

PI US 5371186 19941206

AI US 1992-819893 19920116 (7)

DCD 20111025

RLI Continuation-in-part of Ser. No. US 1991-658744, filed on 11 Feb 1991, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Lee, Lester L.; Assistant Examiner: Davenport, A. M.

LREP Hedman, Gibson & Costigan

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel **peptides** of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or

an

amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The **peptides** are used inter alia for the

prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.

L14 ANSWER 6 OF 12 USPATFULL

AN 93:107024 USPATFULL

TI Method of inhibiting the activity of leukocyte derived cytokines

IN Mandell, Gerald L., Earlysville, VA, United States

Sullivan, Gail W., Charlottesville, VA, United States

Novick, William J., Lebanon, NJ, United States

PA Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ, United States  
(U.S. corporation)

University of Virginia Alumni Patents Foundation, Charlottesville, VA,  
United States (U.S. corporation)

PI US 5272153 19931221

AI US 1992-908929 19920702 (7)

DCD 20080615

RLI Continuation of Ser. No. US 1991-700522, filed on 15 May 1991, now  
abandoned which is a continuation of Ser. No. US 1990-622138, filed on

5

Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of  
Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a  
continuation of Ser. No. US 1988-239761, filed on 2 Sep 1988, now  
abandoned which is a continuation of Ser. No. US 1986-947905, filed on  
31 Dec 1986, now abandoned And a continuation of Ser. No. US  
1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271

DT Utility

FS Granted

EXNAM Primary Examiner: Nutter, Nathan M.

LREP Finnegan, Henderson, Farabow, Garrett & Dunner

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A family of compounds effective in inhibiting interleukin-1 (IL-1)  
activity, tumor necrosis factor (TNF) activity, and the activity of  
other leukocyte derived cytokines is comprised of 7-(oxoalkyl)  
1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and  
R.sub.2 are the same or different and are selected from the group  
consisting of straight-chain or branched alkyl radicals with 2 to 6  
carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A  
represents a hydrocarbon radical with up to 4 carbon atoms which can be  
substituted by a methyl group. Another family of effective compounds is  
identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines  
in mammals is implicated in alleviation of a wide variety of disease  
conditions.

L14 ANSWER 7 OF 12 USPATFULL

AN 93:22715 USPATFULL

TI Method of inhibiting the activity of leukocyte derived cytokines

IN Mandell, Gerald L., Earlysville, VA, United States

Sullivan, Gail W., Charlottesville, VA, United States

Novick, William J., Lebanon, NJ, United States

PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States  
(U.S. corporation)

University of Virginia Alumni Patents Foundation, Charlottesville, VA,  
United States (U.S. corporation)

PI US 5196430 19930323

AI US 1991-762200 19910918 (7)

DCD 20071023

RLI Division of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented,  
Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535,  
filed on 11 Apr 1990, now abandoned which is a continuation of Ser. No.  
US 1988-239761, filed on 2 Sep 1988, now abandoned which is a  
continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now

abandoned which is a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271 which is a continuation-in-part of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Nutter, Nathan M.

LREP Finnegan, Henderson, Farabow, Garrett & Dunner

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1535

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branch alkyl radicals with 2 to 6

carbon

atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L14 ANSWER 8 OF 12 USPATFULL

AN 93:22714 USPATFULL

TI Method of inhibiting the activity of leukocyte derived cytokines

IN Mandell, Gerald L., North Garden, VA, United States

Sullivan, Gail W., Charlottesville, VA, United States

Novick, William J., Lebanon, NJ, United States

PA Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ, United States  
(U.S. corporation)

University of VA Alumni Patents Foundation, Charlottesville, VA, United States (U.S. corporation)

PI US 5196429 19930323

AI US 1991-738096 19910730 (7)

RLI Continuation of Ser. No. US 1990-622138, filed on 5 Dec 1990, now patented, Pat. No. US 5096906 which is a continuation of Ser. No. US 1990-508535, filed on 11 Apr 1990, now abandoned which is a

continuation

of Ser. No. US 1988-239761, filed on 2 Sep 1988, now abandoned which is a continuation of Ser. No. US 1986-947905, filed on 31 Dec 1986, now abandoned And a continuation of Ser. No. US 1987-131785, filed on 11 Dec 1987, now patented, Pat. No. US 4965271 which is a continuation-in-part of Ser. No. US 1986-947905, filed on 31 Dec 1986

DT Utility

FS Granted

EXNAM Primary Examiner: Nutter, Nathan M.

LREP Finnegan, Henderson, Farabow, Garrett & Dunner

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 6 Drawing Page(s)

LN.CNT 1344

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be

substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.

L14 ANSWER 9 OF 12 USPATFULL

AN 89:14777 USPATFULL

TI Method for reducing bacterial endotoxin contamination in solutions of macromolecules

IN Karplus, Thomas E., Sydney, Australia

Ulevitch, Richard J., Del Mar, CA, United States

Wilson, Curtis B., San Diego, CA, United States

PA Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)

PI US 4808314 19890228

AI US 1987-98299 19870918 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Sever, Frank

LREP Dressler, Goldsmith, Shore, Sutker & Milnamow, Ltd.

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention contemplates a method of reducing a bacterial endotoxin contaminant in a biologically useful macromolecule. AN aqueous

medium containing an endotoxin-contaminated macromolecule is admixed with a dialyzable surfactant, and the admixture so formed is contacted with an endotoxin sorbant to form a solid-liquid phase admixture. The contacting is maintained until the endotoxin is bound to the sorbant. The surfactant is dialyzed out of the aqueous liquid phase at a time no earlier than the maintenance step. The liquid phase containing the macromolecule is separated and recovered.

L14 ANSWER 10 OF 12 USPATFULL

AN 83:11238 USPATFULL

TI Immunologically active dipeptidyl saccharides and methods of preparation

IN Durette, Philippe L., New Providence, NJ, United States

Shen, Tsung-Ying, Westfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4377570 19830322

AI US 1980-193777 19801003 (6)

RLI Division of Ser. No. US 1979-7108, filed on 29 Jan 1979, now patented, Pat. No. US 4256735

DT Utility

FS Granted

EXNAM Primary Examiner: Hazel, Blondel

LREP Perrella, Donald J., Pfeiffer, Hesna J.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1,2

DRWN No Drawings

LN.CNT 1516

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;

R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;

R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;



R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);

R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,

R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or substituted benzyl;

R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;

provided that when R.sub.3 is lower alkyl, the stereochemistry at asymmetric center I can be either D or L, but that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, the stereochemistry at I cannot be D;

when R.sub.7 is not H, the stereochemistry at asymmetric center II is either L or D; and

the stereochemistry at asymmetric center III is D.

These compounds possess immunostimulatory properties.

L14 ANSWER 11 OF 12 USPATFULL

AN 83:1781 USPATFULL

TI Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation

IN Shen, Tsung-Ying, Westfield, NJ, United States

Durette, Philippe L., New Providence, NJ, United States

Dorn, Jr., Conrad P., Plainfield, NJ, United States

Doherty, James B., New Milford, NJ, United States

Dean, Richard T., Fanwood, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4368190 19830111

AI US 1980-141227 19800417 (6)

DT Utility

FS Granted

EXNAM Primary Examiner: Hazel, Blondel

LREP Perrella, Donald J., Speer, Raymond M., Pfeiffer, Hesna J.

CLMN Number of Claims: 34

ECL Exemplary Claim: 1,33,34

DRWN No Drawings

LN.CNT 1240

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immunologically active compounds of the formula: ##STR1## wherein:  
R.sub.1 is C.sub.1-7 alkyl; substituted C.sub.1-7 alkyl; phenyl; or substituted phenyl;

R.sub.2 is hydrogen; C.sub.1-7 alkyl; substituted C.sub.1-7 alkyl; phenyl; substituted phenyl; phenyl C.sub.1-4 alkyl; or substituted phenyl C.sub.1-4 alkyl;

R.sub.3 and R.sub.4 may be the same or different and are each independently hydrogen, provided that R.sub.3 and R.sub.4 may not both be hydrogen; or ##STR2## where X is --O--; --S--; or ##STR3## R.sub.10 is hydrogen; C.sub.1-30 alkyl; C.sub.2-30 alkenyl; C.sub.1-30 alkoxy; phenyl; C.sub.1-20 alkylsulfonyl; or cholesteryl;

R.sub.11, R.sub.12, R.sub.13, R.sub.14, and R.sub.15 may be the same or different and are each independently hydrogen; C.sub.1-20 alkyl; C.sub.1-20 alkylcarbonyloxy; amino; benzyl; C.sub.1-20 alkoxyethyl; C.sub.1-20 alkylamido; or ##STR4## r is 0 or 1; s is 0 or 1; and t is

to 20; provided that s may only be 0 when both r and t are greater than 0 or when r is 0 and R.sub.10 is amino; phenyl; substituted phenyl; 1-adamantyl; or heterocycle selected from the group consisting of 2- or 3-furyl, 2- or 3- thienyl, 2- or 3- pyrrolidinyl, 2-, 3- or 4- pyridyl, and 1-tetrazolyl, said heterocycle optionally substituted with C.sub.1-20 alkylcarbonyl; and where R.sub.3 or R.sub.4 is other than hydrogen, the other of R.sub.3 and R.sub.4 may additionally be C.sub.1-4 alkylcarbonyl;

R.sub.5 is hydrogen or C.sub.1-10 alkyl;

R.sub.6 is hydrogen or R.sub.6 and R.sub.7 taken together are --(CH.sub.2).sub.3 --;

R.sub.7 is hydrogen; C.sub.1-7 alkyl; hydroxymethyl; mercaptomethyl; benzyl; or substituted benzyl;

R.sub.8 and R.sub.9 may be the same or different and are each independently COOR, or CONR'R", where R is hydrogen or C.sub.1-7 alkyl, and R' and R" are hydrogen or C.sub.1-3 alkyl;

when R.sub.5 is C.sub.1-10 alkyl, the stereochemistry at asymmetric center I is D or L;

when R.sub.7 is other than hydrogen, the stereochemistry at asymmetric center II is L; and the stereochemistry at asymmetric center III is D; and acid addition and quaternary salts thereof.

L14 ANSWER 12 OF 12 USPATFULL

AN 81:14980 USPATFULL

TI Immunologically active dipeptidyl saccharides and methods of preparation

IN Durette, Philippe L., New Providence, NJ, United States

Shen, Tsung-Ying, Westfield, NJ, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

PI US 4256735 19810317

AI US 1979-7108 19790129 (6)

DT Utility

FS Granted

EXNAM Primary Examiner: Phillips, Delbert R.; Assistant Examiner: Hazel, Blondel

LREP Perrella, Donald J., Levitt, Julian S.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1,14

DRWN No Drawings

LN.CNT 1559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 2-Amino-2-deoxy-glycoses of the general structural formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl (1-7C), substituted alkyl (1-7C), phenyl, substituted phenyl, benzyl, or substituted benzyl;

R.sub.2 is alkyl, substituted alkyl, phenyl, or substituted phenyl;

R.sub.3 is H or lower alkyl (1-10C) with the proviso that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, R.sub.3 cannot be H;

R.sub.4 and R.sub.5 are same or different and are H, aliphatic or aromatic acyl (2-21C) or substituted acyl (2-21C);

R.sub.6 is H, or R.sub.6 -R.sub.7 together is --CH.sub.2 --CH.sub.2 --CH.sub.2 --,

R.sub.7 is H, alkyl (1-7C), hydroxymethyl, mercaptomethyl, benzyl, or

substituted benzyl;

R.sub.8 and R.sub.9 each is carboxyl, esterified carboxyl (1-7C), amidated carboxyl, or mono- or di-alkyl-(1-3C)-amidated carboxyl;

Provided that when R.sub.3 is lower alkyl, the stereochemistry at asymmetric center I can be either D or L, but that when the aminoglycose has the 2-amino-2-deoxy-D-glucose configuration, the stereochemistry at I cannot be D;

When R.sub.7 is not H, the stereochemistry at asymmetric center II is either L or D; and

The stereochemistry at asymmetric center III is D.

These compounds possess immunostimulatory properties.